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Abstract  
Cancer is a major cause of morbidity and mortality with increasing incidence 
worldwide. Early detection of cancers and better treatments would improve the 
outcome for patients. The overall 5-year survival rates of head and neck squamous 
cell carcinoma have not improved in the past several decades due to diagnosis at 
advanced stages and recurrent disease. Early detection and improved 
chemotherapy drugs are two key areas that are required to help to improve the 
prognosis for this disease. 
This thesis focuses on the enzyme telomerase which is known to contribute to one of 
the hallmarks of cancer (immortality).  Elevated telomerase activity has been 
observed in the majority of cancer cells but not in most normal human cells so there 
is an opportunity to use telomerase as a biomarker for disease. This first part of this 
study assessed telomerase activity in saliva and tissues of head and neck squamous 
cell cancer patients. The Telomerase PCR-ELISA kit was used to assess telomerase 
activity in the saliva of patients with confirmed oral carcinomas and its expression 
was analysed in paraffin embedded tissue using immunohistochemistry (IHC). Whilst 
telomerase was detected in cell lines, no telomerase activity was detected in saliva 
samples from patients but was detectable in IHC specimens. 
The second part of the study focused on the pharmacological evaluation of a series 
of small molecule G–quadruplex DNA binding agents as potential telomerase 
inhibitors.  A total of 19 telomerase inhibitors were identified but of these, only 4 were 
specific inhibitors of telomerase.  These compounds also caused toxicity to cell lines 
following a 2 hour drug exposure at doses that also inhibit telomerase activity.  
Further studies are required to explore these compounds further.  
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In conclusion, the results of this study have demonstrated that detection of 
telomerase activity I the saliva of patients with oral cancers is unlikely to be useful in 
terms of detecting oral cancers before symptoms of the disease are clinically 
manifest. A series of novel and specific inhibitors of telomerase have been identified 
and further studies are required to develop these compounds further.  
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1 INTRODUCTION 
1.1 Cancer 
The term cancer usually refers to malignant tumours that have the ability to invade 
and destroy surrounding normal tissues and spread to distant sites. A tumour is a 
term used to describe a diverse group of conditions associated with uncontrolled cell 
replication. Tumours that do not metastasize and remain confined to a specific site 
are classified as benign tumours. Cancers are formed when cells escape the normal 
growth regulating processes to extend beyond the normal confines of that tissue 
The tissue of origin gives the cancer distinguishing characteristics therefore 
pathologically, cancers are classified as: (i) Carcinoma which originate from epithelial 
cells in the skin, or tissues that line or cover internal organs, (ii) Sarcoma – 
originating in bone, cartilage, fat, muscle, blood vessels, or other connective tissue 
(iii) Leukemia – originating in blood forming tissues such as bone marrow, which 
causes large numbers of abnormal blood cells to be produced into the blood stream 
and (iv) Lymphoma - originate in the cells of the immune system. 
In the UK, more than 200 different types of cancers occur but four of them – breast, 
lung, colorectal and prostate account for over half of the new cases (figure 1). The 
20 most commonly diagnosed cancers in the UK are shown in figure 2 (UK cancer 
incidence statistics 2015, Cancer Research UK) 
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Figure 1: Cancer incidence in the UK in 2015 (Cancer research UK) 
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Figure 2: The 20 most commonly diagnosed cancers (excluding non melanoma skin cancer) in 
the UK 2015 (Cancer research UK). 
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Cancer is a major disease burden worldwide and approximately 14 million people 
were diagnosed with cancer in 2012. Worldwide, it is a leading cause of death, 
accounting for 8.8 million deaths in 2015 and deaths from cancer are expected to 
rise by about 70% over the next 2 decades (WHO Cancer fact sheet 2018). Cancer 
is responsible for more than 1 in 4 of all deaths in the UK, and more than 1 in 3 
people in the UK will develop some form of cancer in their lifetime (Cancer statistics 
key facts, Cancer research UK 2015). The economic impact of cancer is significant 
and total annual economic cost in 2010 was estimated at approximately US $1.16 
trillion (Stewart and Wild 2014). It is therefore a condition with major socioeconomic 
impact requiring great efforts to improve current strategies for detection and 
treatment. 
1.2 Aetiology  
The precise cause of cancers is unknown, but most cancers are thought to have a 
multifactorial aetiology. Cancers are thought to occur due to alterations to the DNA 
sequence (mutation), caused by either genetic or environmental factors. Genetic 
factors such as familial disposition and chromosomal abnormalities are thought to be 
associated with increased incidence of cancer. External agents which have been 
identified in the cause of cancer include environmental factors such as irradiation, 
chemicals (such as asbestos and tobacco) and infectious agents (viruses). 
 Nowell (1976) proposed that most cancers arise from a single cell, and progression 
results from the accumulation of genetic changes within the original clone which 
confer a growth advantage in the cancer cells over normal cells. In the past 30 years, 
there has been a tremendous increase in information on the molecular basis of 
cancer development, made possible by the breakthroughs in methodologies of 
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molecular biology in the early 1980’s and 90’s. It has been shown that cancers 
typically arise from alterations in pathways that regulate cellular signaling involving 
DNA damage response, cell cycle arrest and apoptosis. Normal growth control is 
regulated by two different types of genes: proto-oncogenes whose normal cellular 
function is to accelerate cell proliferation, and tumour suppressor genes, which 
function to inhibit cell proliferation. If this balance between proto-oncogenes and 
tumour suppressor genes is disturbed due to mutation in these genes, this could 
result in the development of cancer. The mutations have been shown to occur in a 
multistep process over a long period of time. The most intensely studied model of 
tumor progression is colorectal cancer, a model proposed by Bert Vogelstein 
(Fearon and Vogelstein 1990), which links histological features in the progression of 
colorectal cancer to specific genetic lesions. Mutation of the familial polyposis gene 
APC constitutes the initiating event, additional genetic lesions are associated with 
polyps of increasing severity, and finally, inactivation of p53 commonly marks the 
transition to invasive colorectal cancer. In other tumor types, this progression may be 
driven by the loss of different tumor suppressor genes or by a different cumulative 
order in the inactivation of the same genes, including p53. The model of tumor 
progression of head and neck cancer will be discussed in subsequent chapters. 
Hanahan and Weinberg (2000) proposed that during the development of cancer, 
cells acquire a number of characteristics or traits that they called ‘hallmarks’ - these 
are summarized in figure 3. In their original paper in 2000 (figure 3), six hallmarks 
were defined.  These include: (i) self sufficiency in growth signaling (ii) insensitivity to 
antigrowth signals (iii) evading apoptosis (iv) limitless replicative potential (v) 
sustained angiogenesis and (vi) tissue invasion and metastasis. In an update to their 
2000 paper, Hanahan and Weinberg (2011) described two emerging hallmarks of 
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cancer and two enabling characteristics (figure 4). The emerging hallmarks were: 
metabolic reprogramming and evasion of immunsurveilance and the enabling 
characteristics were: genetic instability and inflammation (Hanahan and Weinberg 
2011).  
 
 
 
 
 
 
 
 
 
 
Figure 3 The hallmarks of cancer as originally described by Hanahan and Weinberg in 2000 
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Figure 4. Emerging hallmarks and enabling characteristics (Hanahan and Weinberg 2011) 
 
Among these hallmarks, the acquisition of unlimited replicative potential is a key step 
to ensure expansive tumour growth (Olaussen et al. 2006). An enzyme called 
telomerase has been identified as providing cancer cells with unlimited replicative 
capacity described. Hayflick (1997) demonstrated that cultured cells have a finite 
replicative potential and undergo a certain number of doublings, after which they 
stop growing (a process termed senescence) or undergo cell death. On the other 
hand, cancer cells in culture have the ability to multiply without limit and this 
characteristic represents the hallmark of replicative immortality of cancer cells. 
Telomerase is a ribonucleoprotein complex with enzymatic activity responsible for 
the maintenance of telomeres, which cap and protect the ends of chromosomes.  
The thesis described here will be focusing on telomerase, its detection and also its 
position as a target for cancer therapeutics. The structure and function of telomerase 
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will be discussed in subsequent chapters but initially, context is provided by briefly 
reviewing key aspects of cancer diagnosis, treatment and drug development. 
 
1.3 Diagnosis of cancer 
The diagnosis of cancer is made from clinical history and investigation of symptoms. 
Clinical manifestation of cancer varies depending on the local effect of the primary 
tumour and effects on any site of metastatic spread. Investigations include routine 
blood tests, tests for tumour markers in body fluids, genetic tests and radiological 
investigations. Tissue diagnosis is made from tissue samples obtained from 
abnormal areas which are subjected to histological analysis. Histological features of 
cancerous growths include cellular de-differentiation, invasion of adjacent tissues, 
and microscopic evidence of metastasis. A cancerous tissue shows cellular 
abnormalities such as: local increase in cell number, loss of the normal regular 
arrangement of cells, variation in cell shape and size, increase in nuclear size and 
density of staining, increase in mitotic activity, and presence of abnormal mitosis and 
chromosomes. Variability however can occur amongst histopathologists in the 
interpretation of histological findings which can limit in diagnostic histopathology 
(Soyer et al. 2005).  
 
1.4 Cancer therapy 
The ideal way to defeat cancer would be to prevent it and education of individuals 
about environmental factors and avoidance of them would play a role reducing the 
incidence. Coupled with this, early detection of cancer before it has metastasized 
would also contribute significantly to improving survival as surgery and radiotherapy 
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are effective at treating localised tumours. The reality is however that many cancers 
have spread by the time they are diagnosed and others (leukaemia / lymphoma) are 
disseminated from the onset. Systemic based therapies are therefore required, and 
the following subsections provide an overview of current treatment strategies 
together with their limitations.  
1.4.1 Surgery 
Surgery offers a means of local treatment. It may have several components (i) tissue 
biopsy to establish diagnosis and (ii) removal of malignant disease with clear 
margins of normal tissue. The type of surgery required is determined by the type of 
tumour and anatomical site. This may include (i) wide local excision of the tumour 
mass, (ii) removal of part of an organ and surrounding tissue and (iii) removal of an 
entire organ. In the context of head and neck cancer, this may include for example, 
partial removal of the tongue in carcinoma of the tongue or laryngectomy (removal of 
the larynx) in carcinoma of the larynx. This may have resulting long term morbidity 
with impaired physiological functions of speech and swallowing. Organ preservation 
is therefore a goal of treatment. 
1.4.2 Radiotherapy 
This is the use of ionizing radiation to treat disease. Ionizing radiation may be 
delivered by X-ray beams, beams of ionizing particles (for example electrons) or by 
beta or gamma irradiation produced by the decay of radioactive isotopes. It offers a 
means of loco-regional control of cancer, covering a wider area and is less 
constrained by anatomical boundaries and surgical technique. It can be used alone 
or in combination with surgery and/or chemotherapy. In early stage head and neck 
cancer, it provides a highly effective means of cure.   
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1.4.3 Chemotherapy 
Cancer chemotherapy is the use of cytotoxic agents to destroy cancer cells. 
Compared to surgery and radiotherapy, chemotherapy is a relatively new method of 
treatment having been developed in the 1940s following the successful use of 
mustard derived compounds in humans (Goodman and Gilman 1946). Surgery had 
been used to treat localized disease for more than a century and radiotherapy for a 
quarter of a century before the first chemotherapy was given to a patient. 
Chemotherapy is a systemic form of treatment using drugs that are often highly toxic 
since they are rarely selective for cancer cells. The common basis of the activity of 
these agents is that they kill dividing cells by either inhibition of DNA replication or by 
acting as mitotic poisons. Chemotherapy agents can be classified into (i) drugs 
acting on the structure of DNA such as antimetabolites, alkylating agents, 
intercalating agents and topoisomerase inhibitors, (ii) drugs acting on mitosis  such 
as spindle poisons, (iii) signal transduction inhibitors, (iv) drugs inducing apoptosis 
and (v) drugs targeting the tumour vasculature (Neal and Hoskin 2009). 
Chemotherapy may be used alone but is more often used in combination with 
surgery or radiotherapy as an adjuvant to loco- regional treatment to enhance local 
control and attack potential sites of metastasis. One of the limitations in using 
chemotherapeutic agents is toxicity to normal tissues, as the majority of agents are 
non-specific in their action resulting in damage to both malignant and normal cells. 
Common limitation toxicities include bone marrow suppression, bowel toxicity, renal 
and neurological damage. Another drawback of chemotherapy is the development of 
drug resistance which can be an intrinsic property of the malignant cell or acquired 
by the cells after exposure to individual drugs. Development of resistance is the main 
cause of treatment failure following an initial good response to chemotherapy. The 
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concept of drug resistance and the recognition of the frequency with which it occurs 
underlie the use of drug combinations for systemic therapy. In head and neck 
cancers, multi-agent chemotherapy (along with radiotherapy), have been shown to 
improve survival rates (Garden et al 2001). 
1.5 Target oriented approach to cancer therapy 
Cancers arise from normal human cells, and chemotherapy is often highly toxic and 
rarely selective for cancer cells which have made the chemotherapeutic approach to 
the treatment of cancers challenging. In recent decades there have been advances 
in the knowledge of the molecular and biological traits of cancer cells which 
distinguish them from normal cells. These molecular and biochemical changes have 
therefore become potential targets for drug development. Targeted cancer therapies 
are drugs or other substances that block the growth and spread of cancer by 
interfering with specific molecules that are involved in the growth, progression and 
spread of cancer. Rather than using broad based cancer treatments, focusing on 
specific molecular changes which are unique to a particular cancer, targeted cancer 
therapies may be more therapeutically beneficial for many cancer types (Baudino T. 
2015). Current cancer research activities are focused on targeted drug development, 
with drugs designed to block tumour specific receptors and proteins and this has led 
to promising novel agents being evaluated. These new classes of cancer targeted 
drugs which have emerged can be categorized according to their respective effects 
on one or more of the hallmark capabilities. Figure 5 below is an illustration of the 
acquired capabilities of cancer cells as described by Hanahan and Weinberg (2011), 
showing the mechanism of action of drugs that interfere with the molecular 
processes (‘targets’), which enable cancer cells to acquire the hallmarks of cancer.  
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Figure 5 Therapeutic targeting of the hall marks of cancer (Hanahan and Weinberg, 2011) 
 
 
. Most targeted therapies are either small molecule inhibitors or monoclonal 
antibodies. The most successful small molecule inhibitor so far has been Imatinib 
mesylate (Gleevec), which is a tyrosine kinase inhibitor that targets Bcr-Abl and one 
of the first targeted drugs to be developed. It is used in the treatment of chronic 
myeloid leukaemia and has revolutionised the treatment of these group of patients 
with improved 10 year survival rates (Hochhaus et al. 2017). It is also used in the 
treatment of gastrointestinal stromal tumours via its ability to inhibit c-kit. It has 
relatively few side effects and is a success story in the development of targeted 
therapies. An example of monoclonal antibodies includes inhibitors of angiogenesis 
(VEGF inhibitors) which in randomised control clinical trials (Murukesh et al 2010) 
have demonstrated an improvement in response, progression free survival or overall 
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survival when used to supplement conventional therapy, in colorectal cancer patients 
and breast cancer patients. Bevacizumab (Avastin) is an example of a VEGF 
inhibitor (Ranieri et al. 2006). Another class of targeted agents includes inhibitors of 
proliferative signalling - EGFR inhibitors (Dziadziuszko & Jassem. 2012) such as 
Erlotinib (Rosell et al. 2012), Gefitinib (Mitsudomi et al. 2010) and Cetuximab (Van 
Cutsem et al. 2015) which have also demonstrated improvement in response and 
progression free survival. However, an issue with most targeted drugs is that clinical 
responses have been transitory followed by relapses. Experimental evidence 
suggests that the targeted agent may not completely shut off a hallmark capability, 
allowing some cancer cells to survive with residual function, until they are able to 
develop adaptive resistance or reduce their dependence on a particular hallmark 
capability and become more dependent on another (Hanahan and Weinberg 2011; 
Azam et al 2010). The most common side effects seen with targeted therapies are 
diarrhoea and liver problems. Other side effects include skin problems, hypertension, 
clotting and wound healing problems. 
Table 2 below shows examples of drugs that have been developed that interfere with 
the acquired capabilities necessary for tumour growth and development. The 
hallmark ‘enabling replicative mortality’ looking at telomerase and telomerase 
inhibitors will be the area of focus of this thesis. This will be discussed further in 
subsequent chapters. 
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Acquired 
capability 
Molecular 
mechanisms 
             Drugs References 
Sustaining 
proliferative 
signaling 
EGFR inhibitors 
(Dziadziuszko & 
Jassem 2012) 
Gefitinib 
 
Erlotinib 
Cetuximab 
Mitsudomi et al, 
2010 
Rosell et al. 2012 
Van Cutsem et al. 
2015 
Evading growth 
suppressors 
Cyclin dependent 
kinase inhibitors 
(Sánchez-Martínez 
et al. 2015) 
Palbociclib 
 
Finn et al. 2015 
Resisting 
programmed cell 
death 
Proapoptotic BH3 
mimetics (Bcl-2 and 
Bcl-XL inhibitors) 
 
(Zhang et al. 2007) 
GX015-070 
 
 
 
 
TW-37 
 
 
 
ABT-737 
Li et al., 2007; 
Perez- Galan et al. 
2007; Hwang et al. 
2010 
 
Mohammad et al 
2007; Wang et al. 
2008 
 
Del Gaizo Moore et 
al. 2007; Deng et al. 
2007; van Delft et 
al. 2006 
Enabling replicative 
immortality,  
Telomerase 
inhibitors 
GRN163L Herbert et al 
2005; Roth et al. 
2010 
Inducing 
angiogenesis,  
Inhibitors of VEGF 
signaling  
(El-Kenawi and El-
Remessy. 2013) 
Bevacizumab 
 
 
Vatalanib 
 
Sunitinib 
Reck et al. 2009; 
Strickler and 
Hurwitz. 2012 
Dragovich et al. 
2014 
Socinski et al. 2008; 
Novello et al. 2009 
Tissue invasion and 
metastasis 
Inhibitors of HGF/c-
Met  
(Blumenschein et al. 
2012) 
Rilotumumab 
 
Cabozantinib 
 
Foretinib 
Tivantinib 
Schoffski et al. 
2011 
Kurzrock et al. 2011 
 
Seiwert et al. 2009 
Santoro et al. 2010 
 
Table 1 Drugs that interfere with the acquired capabilities necessary for tumour growth and their 
molecular mechanisms 
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1.6 Head and neck squamous cell cancer (HNSCC) 
For the purpose of this study, head and neck squamous cell cancer (HNSCC) refers 
to squamous cell carcinoma involving the oral cavity (tongue, floor of mouth, buccal 
mucosa, lower alveolus, upper alveolus and hard palate) and pharynx (Figure 6).  
 
 
Figure 6 Anatomy of the upper aero-digestive tract (Holland – Frei manual of cancer medicine 2005)     
 
The overwhelming majority of head and neck cancers are squamous cell carcinoma 
which account for more than 90% of malignant tumours of the oral cavity (Daley and 
Darling 2003). HNSCC accounts for approximately 2% of all carcinomas in the UK 
(UK cancer statistics – Cancer Research UK 2015) and worldwide, oral and 
pharyngeal carcinoma grouped together is the 6th commonest cancer, with two thirds 
of the cases arising in developing countries (Warnakulasuriya 2009). In most 
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countries, the five-year survival rates for cancers of the tongue, oral cavity and 
oropharynx are around 50% (Warnasurakuriya 2009). 
1.6.1 Aetiology 
The most important aetiological factors for head and neck cancers include excessive 
intake of tobacco (either by smoking or chewing), and alcohol, either as independent 
risk factors, or as a synergistic effect (Decker and Goldstein 1982; Maier et al. 1992). 
The risk for development of oral cancer is 3 to 9 times greater in those who smoke or 
drink and as much as 100 times greater in those who both smoke and drink heavily 
than in those who neither smoke nor drink (Mao et al. 2004; Neville and Day 2002). 
Human papilloma virus has also become a major etiological factor in a subset of 
HNSCC (Lopes et al. 2011). Other risk factors implicated include poor hygiene in the 
oral cavity, environmental contaminants such as paint fumes, dietary factors and use 
of marijuana (Petti 2009). 
1.6.2 Diagnosis/ staging 
The gold standard for diagnosis of head and neck cancer is biopsy of a clinically 
suspicious area and histological analysis of the specimen. It is graded histologically 
as well differentiated, moderately differentiated or poorly differentiated carcinoma.  
Head and neck tumours are staged by the UICC: TNM of malignant tumours       
(UICC -International Union Against Cancer; TMN – Tumour / Node / Metastasis). 
This classification describes the anatomical extent of the disease based on an 
assessment of the following categories: the extent of the primary tumour (T), the 
absence or presence and extent of regional lymph node involvement (N) and 
absence or presence of distant metastatic spread (M). The categories are grouped 
together as a stage grouping – I, II, III, IV, V (Fleming et al.1997; Sobin et al. 2009). 
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Stages I and II denote early stage disease and stages III – V late stage disease. This 
staging system helps to guide treatment selection in clinical practice, and it has been 
shown that survival is strongly associated with TNM stage. 
1.6.3 Molecular epidemiology 
Like most epithelial cancers, HNSCC develops through the accumulation of multiple 
genetic and epigenetic alterations in a multistep process. Many of these alterations 
occur early and have been identified in premalignant lesions of the head and neck 
(Mao et al. 2004). The most common of all the genetic changes is loss of 
chromosomal region 9p21 which is an early event (Van der riet et al. 1994). Mao et 
al (1996) also showed alterations at chromosomes 9p21 and 3p14 in oral 
premalignant lesions. The p53 tumour suppressor gene has also been shown to be 
the most frequently mutated gene in HNSCC (Brennan et al. 1995). Gene 
amplification (cyclin D1) and protein overexpression (EGFR – epidermal growth 
factor receptor) have also been found (Izzo et al. 2003; Pomerantz and Grandis 
2003).  
Reactivation of telomerase is another early event in the tumourigenic process of 
HNSCC (Mao et al. 1996; Mutirangura et al. 1996), which prolongs the survival of 
cells with genetic abnormalities making accumulation of multiple genetic alterations 
possible. These genetic alterations may be used as potential tumour markers for the 
detection of cancer cells in clinical samples such as saliva. It has been suggested 
that early genetic changes may not necessarily correlate with observed cellular 
changes (Rosin et al. 2000; Partridge et al, 2000). This implies that cells may appear 
normal on histological analysis but may have undergone molecular changes. 
Califano et al (1996) delineated a model of molecular progression of HNSCC from 
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preneoplastic lesions to invasive cancer by analysing head and neck lesions at 
various stages of tumourigenesis to detect deletions of multiple chromosomal 
regions. They showed that molecular change may be present in areas of 
premalignant change before cellular phenotypic changes become detectable. 
Spafford et al (2001) demonstrated that molecular analysis of cells collected by 
rinsing the mouth showed the same changes as were present in tumour biopsy 
specimens.  
1.6.4 Treatment of head and neck squamous cell cancer 
The mainstay of treatment of early stage HNSCC is surgery and radiotherapy, or 
radiotherapy alone (Belcher et al. 2014). Systemic chemotherapy has traditionally 
been used as palliative therapy for recurrent/advanced stage (III and IV) head and 
neck cancer, but randomized trials have demonstrated an improvement in disease 
control rates using a combination of chemotherapy and radiotherapy, rather than 
either method alone (Zhang et al. 2013). One of the aims of treatment of HNSCC is 
preservation of organ function and this has been the goal of surgical innovation in 
the last decade. The use of combined modality treatment regimens (such as surgery 
and radiotherapy/chemotherapy) helps to preserve crucial organs such as the larynx 
and the tongue. The type of treatment offered depends on the stage of the disease 
based on the TMN classification. Advancement in understanding molecular 
mechanisms have led to development of therapies that specifically target the 
molecular pathways commonly dysregulated in Head and Neck cancers (for example 
overexpression of EGFR). An example of this is Cetuximab, (a monoclonal antibody 
which targets EGFR), which has been shown to improve overall survival when 
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combined with other chemotherapeutic agents or radiotherpay (Vermorken et al. 
2008; Bonner et al. 2006). 
 
1.7 The telomere / telomerase complex 
The structures at the ends of eukaryotic chromosomes are termed telomeres. 
Telomeres are DNA – protein structures composed of tracts of repetitive 
hexanucleotide sequences (5’-TTAGGG-3’ termed “G – rich strand” and                  
5’-CCCTAA-3’ termed “C – rich strand”, for human telomeres). Telomeres protect 
chromosomes from degradation and loss of essential genes, and allow the cell to 
distinguish between double strand breaks and natural chromosome ends (Shay and 
Wright 2006). In mammalian cells, the G – rich strand is longer by several hundred 
nucleotides resulting in a long 3’ single strand overhang (figure 7). Two structures of 
the 3’ telomeric overhang have been proposed. Ultrastructural evidence in vitro 
suggests the 3’ overhang folds back on itself to form a duplex loop structure termed 
the T loop (Doksani et al. 2013). The other proposes the formation of dimers and 
tetramers involving G-quadruplexes (Palm and de Lange. 2008; Lipps and Rhodes. 
2009). 
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Figure 7 Telomeres - the telomeres consist of a variable number of tandem repeats of TTAGGG 
sequence and are therefore of variable length. The G – rich strand at the 3’ end of the telomere 
forms a single stranded extension that can fold back on itself in vitro to form a T loop or G 
quartet structure. (Olaussen et al., 2006). 
 
Linear DNA molecules, such as eukaryotic chromosomal DNA are unable to 
replicate their telomeric ends and require mechanisms besides the conventional 
DNA polymerases to complete the replication of their ends. With each successive 
round of cell division, erosion of the telomere occurs with loss of 50-200 bases of 
telomeric DNA (figure 8). The telomeres eventually become so short that they can no 
longer effectively protect the ends of chromosomes, at which point the cell goes into 
crisis which is characterized by chromosome fusion and widespread apoptotic death 
(this phenomenon was first described by McClintock in 1941). The shortened 
telomeres are recognized as DNA damage which form a telomere dysfunction 
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induced focus (TIF) and typically, cells respond to TIFs through senescence or 
apoptosis (Sekaran et al. 2014) 
 
 
 
Figure 8 Telomere structure – regulation of telomere length in normal and cancer cells by 
telomerase (Keith et al 2001) 
 
 
The proteins associated with telomeres are called the ‘shelterin complex’ which 
consists of 3 core subunits TRF1, TRF2 and POT1, and three additional proteins, 
TIN2, TPP1, RAP1. These proteins form a complex that enable DNA damage 
response surveillance machinery to distinguish telomere DNA from sites of genomic 
DNA damage. Some telomere associated proteins bind directly to the telomeric 
repeats (T2AG3), whilst others are associated with the telomere via protein-protein 
interactions (figure 9). TRF 1 and TRF 2 (telomeric repeat binding factors 1 and 2) 
bind double stranded telomere sequences and POT 1 (protection of telomeres 1) 
associates with the 3’ single stranded overhang. TRF 1, TRF 2, and POT 1 interact 
together and associate directly or indirectly with other proteins such as Tankyrase 1 
and 2 and TIN 2 - TRF1 interacting protein 2 (Jafri et al. 2016). The telomeric DNA 
and telomere associated proteins play an essential role in stabilizing the 
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chromosome ends. The protective function of the telomere is mediated by activities 
of the telomere-associated protein complexes (Lu et al. 2013). 
 
Figure 9 Schematic representation of telomeric DNA and components of the shelterin complex 
(Jafri et al. 2016) 
 
Telomerase is the enzyme responsible for telomere regeneration. It is a ribo–
nucleoprotein enzyme responsible for adding telomeric repeats onto the 3’ ends of 
chromosomes (Greider and Blackburn 1985). It is composed of two essential 
components: a protein subunit TERT – telomerase reverse transcriptase termed 
hTERT in humans (Nakamura et al 1997), and an RNA component – telomerase 
RNA (hTR in humans). Telomerase uses its integral RNA component as a template 
to synthesize telomeric DNA directly onto the ends of chromosomes (Feng et al 
1995). Human telomerase is regulated during development and differentiation, 
mostly through transcriptional control of hTERT. hTR is ubiquitously expressed in 
mammalian cells (Feng et al. 1995), but the expression of hTERT is restricted to 
cells that exhibit telomerase activity. This indicates that hTERT is the rate-limiting 
component of the telomerase enzyme (Xi and Cech. 2014).  
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1.8 Telomerase and cancer 
As previously described, telomeric repeats help maintain chromosomal integrity but 
linear eukaryotic chromosomes are unable to replicate their telomeric ends. In most 
normal human cells, telomeric DNA is progressively lost with each round of cell 
division resulting in the shortening of telomeres to critical length with loss of the 
ability of telomeres to protect the ends of chromosomal DNA and subsequent 
widespread chromosomal fusion and degradation (Blasco et al 1997; Counter et al 
1992). Normal somatic cells exhibit a limited number of replicative cycles in culture 
and this limitation has been associated with two barriers of proliferation (i) 
senescence, a non-proliferative but viable state and (ii) crises leading to cell death. 
In the early 1960’s Leonard Hayflick showed that normal human fibroblasts would 
stop growing after a certain apparently predetermined number of divisions and enter 
into a state known as replicative senescence (Hayflick and Moorhead 1961). The 
limited replicative life span of human cells has been postulated to serve as an 
important barrier to malignant transformation (Sager R 1991; Hahn et al 1999) and 
the ability to bypass replicative senescence is thought to be one critical rate-limiting 
step in the evolution of most malignancies. As previously described, cancer cells 
need to acquire genetic mutations that override the normal mechanisms controlling 
cellular proliferation in order to acquire the ability to multiply indefinitely and therefore 
form malignant tumours.  
Telomerase is the enzyme that provides cancer cells with unlimited replicative 
capacity. It is a specialized enzyme first identified in ciliates by Greider and 
Blackburn in 1985, and it prevents telomeric DNA from being shortened during cell 
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division. In most normal cell types, telomerase activity is down regulated; in cancer 
cells, however, telomerase expression is activated. Telomerase has been found to 
be over expressed in 85-90% of cancer cells such as hepatocellular carcinoma, 
colon cancer, Wilm’s tumour, breast cancer, prostate cancer, brain tumours and 
head and neck squamous cell carcinoma (Kim et al 1994; Shay and Baccetti 1997). 
Telomerase activity is absent in about 15% of malignant tissues and in this situation, 
the tumours maintain the length of telomeres by a non-telomerase based mechanism 
known as alternative lengthening of telomeres (ALT) which also permits unlimited 
replication of cells (Henson et al 2002; Dilley and Greenberg. 2015). Majority of 
somatic cells and benign cells do not express the telomerase activity, but the 
following normal tissues have been found to have increased telomerase activity: 
germ line tissues (Kim et al 1994); haematopoietic stem cells (Broccoli et al 1995) 
and keratinocytes (Harle-Bachor and Boukamp 1996). 
The significance of telomerase in malignant transformation was demonstrated by 
Hahn et al (1999) where they were able to create human tumour ‘like’ cells from 
normal cells via the ectopic expression of the catalytic subunit of telomerase. The 
presence of telomerase activity has also been correlated with a resistance to 
induction of both senescence and crises; conversely, suppression of telomerase 
activity leads to telomere shortening and to the activation of one or the other 
proliferative barriers (Hanahan and Wienberg. 2011). As telomerase activity has 
been found in almost all human cancer tissues and cancer cell lines, it appears to be 
the most universal of all known tumour markers (Kim. 1997; Shay and Bacchetti. 
1997).  
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1.9  Detection of telomerase  
A method of detecting telomerase is via the detection of telomerase activity using the 
telomeric repeat amplification assay (TRAP assay). Other methods of telomerase 
measurement include the detection of telomerase expression (as opposed to 
detection of telomerase activity with the TRAP assay), such as  immunohistological 
detection of hTERT protein in cultured cells and tissue sections and detecting the 
expression of hTERT mRNA using methods to measure RNA expression such as 
northern blotting, in situ hybridization and RT-PCR. Further details of the 
methodologies used in this thesis are described below.  
TRAP assay 
Telomerase enzyme activity is commonly detected and quantified by the polymerase 
chain reaction (PCR)-based assay known as the telomeric repeat amplification 
protocol (TRAP) assay. Previously, the conventional primer-extension based assay 
for detecting telomerase activity required large amounts of sample material and only 
allowed detection of telomerase with limited sensitivity. These disadvantages were 
overcome by the TRAP assay in which the telomerase reaction product is amplified 
by PCR. The amount of PCR product generated is proportional to telomerase protein 
expression and activity. The standard TRAP assay (described by Kim et al 1994) is a 
2 staged PCR based assay. In the first stage, telomerase adds 5’- TTAGGG-3’ 
repeats to the end of a synthetic primer that has a telomere-like sequence. In the 
second stage, the extended products are amplified using a reverse primer 
complimentary to the repeat sequences. The standard TRAP described by Kim et al 
requires a radioactive label and visualization of the PCR amplification products by 
autoradiography after gel electrophoresis.  
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The TRAP assay and variations on this assay are the most widely used methods of 
monitoring telomerase activitiy. Various other modifications have been suggested 
since the introduction of the TRAP assay some of which do not require radioactivity 
and are available as commercial kits. These include: TRAPezeXL - TRAP with 
Amplifluor primers which are energy transfer primers that emit fluorescence only 
upon incorporation into the PCR products of TRAP (Uehara et al.1999) and TRAP-
ELISA (figure 9). TRAP-ELISA assay is based on the principle that a biotinylated 
substrate primer is used to immobilise the denatured PCR product to a streptavidin-
coated microplate, hybridized with a digoxigenin-labelled probe and detected with an 
antibody against digoxigenin conjugated to peroxidise (Longchampt et al 2003; 
Yamamoto and Hirakawa 2005).  
The TRAP assay is highly sensitive and specific for telomerase activity in tumour 
samples (Hess and Highsmith 2002), but it has certain limitations. A drawback of the 
TRAP assay is when it is used on tissue homogenates; the expression of telomerase 
activity in a low number of cells may be masked by its absence in the majority of 
cells in a tissue and also, information on the cell type expressing telomerase is lost. 
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Figure 10 Principle of the TRAP ELISA. Steps 1 and 2– telomerase adds telomeric repeats to the 
3’ end of the biotin labelled synthetic (P1-TS) primer, and the elongation products are 
amplified by PCR using the primers (P1-TS and P2), generating PCR products with telomerase 
specific 6 nucleotide increments. Steps 3 and 4 – the PCR product is hybridized to a 
digoxigenin labelled telomeric repeat specific probe and this is then immobilized via the biotin 
labelled primer to a streptavidin-coated microplate (Roche diagnostics Shi et al 2013; Giri et al 
2009). 
 
Immunohistochemical detection of hTERT protein 
The expression of hTERT protein can be identified in individual cells via 
immunohistochemistry in cultured cells and tissue sections (Hiyama et al 2001). The 
procedure was conceptualized and first implemented by Dr. Albert Coons in 1941. 
Immunohistochemistry exploits the principle of antibodies binding specifically to 
antigens in cells. The antibody-antigen interaction can be visualized in a number of 
ways such as the antibody conjugated to an enzyme, such as peroxidase, resulting 
in a colour-producing reaction. Alternatively, the antibody can also be tagged to a 
fluorophore, such as fluorescein or rhodamine. The TRAP assay described above is 
able to estimate telomerase activity but is unable to determine telomerase activity in 
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each cell. The primary antibody used in this study was the hTERT monoclonal 
antibody – the methodology will be discussed in subsequent chapters. 
 
1.10 Telomerase activity in body fluids 
Telomerase activity has been shown to occur in cytological samples (Yamamoto and 
Hirakawa 2005; Cunningham et al. 1998). Cunningham et al used the TRAP assay 
to detect telomerase expression in fine needle aspirates and fluid specimens from 
different body sites with different histological diagnosis. They found that 6 out of 12 
fine needle aspirate specimens that were cytologically positive for malignant cells 
expressed telomerase activity whilst none of the cytologically atypical or negative 
specimens tested positive for telomerase activity. Four of the six fluid specimens that 
were cytologically positive and 1 of the cytologically negative fluid specimens 
expressed telomerase. Yamamoto and Hirakawa detected telomerase activity in 8 of 
16 malignant cases (ascitic, pleural and pericardial fluid; peritoneal washings) using 
the TRAP assay and 10 of 16 malignant cases using RT PCR to detect hTERT 
mRNA expression. They found that the detection of mRNA expression of hTERT is a 
more useful method than TRAP assay for the detection of cancer cells in body fluids. 
Telomerase activity has also been detected in other body fluids such as urine 
(Melissourgos et al. 2003; Casadio et al. 2009). Using RTPCR, Melissourgos et al in 
2003 were able to detect the expression hTERT in the urine of 92% of patients with 
bladder cancer whilst only 44% yielded a positive result by cytology suggesting a 
more sensitive method of detection. Casadio et al (2009) showed that urine 
telomerase activity was a good marker for early diagnosis of bladder tumours in 
symptomatic patients. 
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1.11 Telomerase and head and neck squamous cell cancer 
As previously described in section 1.7, telomerase activity is down regulated in most 
normal cell types but has been found to be activated and over expressed in 85-90% 
of cancer cells (Kim et al. 1994; Shay and Wright 1996; Shay and Baccetti 1997). 
The fact that telomerase activity is mainly detected in cancerous cells as opposed to 
benign and normal cells has attracted investigations into its possible use as a 
prognostic and diagnostic marker. As with other cancers, telomerase has been found 
to be active in approximately 80% to 90% of tumour tissues of the head and neck 
squamous cell carcinomas whereas it is not active in normal head and neck tissues 
(Mao and El-Nagger 1996; Rossi et al. 2005). Furthermore, telomerase activation 
has been shown to be an early event in the progression of HNSCC (Mao et al. 
1996). Curran et al (1998) were able to detect telomerase activity using the TRAP 
method in 18 of 20 oral cavity squamous cell carcinoma tissues. Expression of the 
telomerase catalytic protein subunit (hTERT) in HNSCC has also been investigated 
by immunohistochemistry. Kim et al (2001) were able to demonstrate elevated levels 
of hTERT expression in paraffin embedded squamous cell carcinoma biopsy 
specimens. Boyle et al (1994) have previously demonstrated the possibility that 
cancer cells may be shed into the saliva of head and neck cancer patients. They 
identified tumour specific mutations from exfoliated cells in saliva that had been 
obtained from the patients preoperatively. Using the PCR-based radioactive methods 
for detection, telomerase activity has been detected in oral rinses of HNSCC patients 
but the rate of detection and level of positivity has been low (Califano et al. 1996; 
Mutiranga et al. 1996; Sumida et al. 1998).  
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Saliva and Head and neck squamous cell cancer 
Whole saliva is a mixed fluid that is derived predominantly from 3 pairs of salivary 
glands. It contains expectorated bronchial and nasal secretions; desquamated 
epithelial cells and other cellular components; and food debris. Some of these 
desquamated epithelial cells could be shed from cancerous tissue. Saliva is 
therefore one of the most reliable tools for diagnosing oral squamous cell 
carcinomas due to its direct contact with oral cancer lesions (Radhika et al. 2016). 
An ideal diagnostic test should be noninvasive, inexpensive, and easy to perform; 
the marker evaluated should be detected in early cancer stage and grade; the test 
should be highly accurate to reduce the rate of false positive and negative results. In 
the context of head and neck cancer, saliva would serve as an ideal substrate to 
investigate biological markers in this disease. 
In 1998, the National Institute of Health Biomarkers Definitions Working Group 
defined a biomarker as ‘a characteristic that is objectively measured and evaluated 
as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention (Biomakers Definitions 
Working Group. 2001). Biomakers have been classified based on biomolecules into 
DNA biomarkers, RNA biomarkers and protein biomarkers (Mishra and Verma. 
2010). The increasing use of biomarkers to assess systemic health and disease 
status has led to study of cancer markers in saliva. 
Saliva is known to contain RNA from various sources such as secretions from 
salivary glands, gingival crevice fluid and desquamated epithelial cells. Saliva has 
been shown to contain ribonucleases (Eichel et al. 1964). It is not clear how RNA 
and ribonucleases can coexist in saliva, but it has been shown by Park et al (2006) 
that salivary RNA is protected from degradation as similarly occurs with plasma RNA 
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(Tsui et al. 2002). Markopoulos et al (2010), in their study on salivary biomarkers for 
oral cancer detection showed that the molecular diagnosis of oral squamous cell 
carcinoma can be explored in three ways – a) changes in cellular DNA which result 
in - b) altered mRNA transcripts leading to - c) altered protein levels intra or extra-
celullarly. Changes in cellular DNA include presence of point mutations, deletions, 
translocations, amplifications and methylations, cyclin D1, epidermal growth factor 
receptor and microsatellite instability (Bano et al. 2015). P53 gene mutations are 
present in saliva samples of patients with head and neck cancers (Liao et al. 2000).  
Li et al (2004) using microarray analysis of the saliva transcriptone showed that 
mRNA levels for specific proteins are elevated in HNSCC, compared to healthy 
control subject. CD44, a cell surface transmembrane glycoprotein which has been 
found to be over-expressed in the earliest stages of carcinogenesis is detectable in 
body fluids and can be measured with simple, inexpensive assays (Dasari et al 
2014).  
 
1.12  The head and neck squamous cell cancer problem 
HNSCC is a complex disease arising from different anatomical sites in the head and 
neck (as above). It is associated with severe disease and treatment related 
morbidities. Despite therapeutic advances in the treatment of HNSCC, the overall 5 
year survival from the disease has remained unchanged over the last 30 years and 
is amongst the lowest of the major cancers. This is largely reflected by the fact that 
most cases are in advanced stages at the time of detection, despite easy 
accessibility for regular examination (Warnasurakuriya 2009). Several factors have 
been shown to be responsible for this low survival rate: 
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Diagnostic problems 
These include  
(i) Diagnostic delay due to patient factors and physician factors (from diagnostic 
difficulty), which result in significant proportions not diagnosed early 
enough and treatment commenced only when they reach an advanced 
stage (McGurk et al. 2005, Allison et al. 1998; Kowalski et al. 1994).  
(ii)  Successfully treated early stage disease patients have a high incidence of a 
second primary tumour cancer of the head and neck (Slaughter et al. 
1953; Jang et al. 2001). However, the prognosis in early stage disease is 
much better than late stage disease and can be as high as 80% as it 
requires much less complex and aggressive treatment (Silverman Jr 1988, 
van der Schroeff and Baatenburg de Jong 2009). 
The entire upper aero digestive tract of head and neck cancer patients is chronically 
exposed to the common etiological carcinogens such as tobacco smoke which 
therefore predisposes the patients to multiple oral precancerous lesions (Jang et al. 
2001). As described previously, most head and neck cancers arise in a 
precancerous field of epithelial cells characterized by tumour associated genetic 
changes. These abnormal fields can be extensive but may not be visible at clinical 
examination (Tabor et al. 2001). Diagnosis is reliant on biopsy of a clinically 
suspicious area and histological analysis of the specimen. This requires a very 
experienced pathologist but variability of interpretation of findings occurs amongst 
pathologists. Slaughter et al (1953) proposed a phenomenon called ‘field 
cancerization’ - they showed that all the epithelium outside an oral squamous cell 
cancer was abnormal and that 11% of the patients had another cancer elsewhere. In 
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this situation, a patient with multiple predisposing factors has a mixture of normal 
cells, potentially malignant cells; malignant cells that have yet to invade and cells 
that have invaded all occurring together. Thus, there can be a considerable 
discrepancy between the clinician’s view of where the lesion is and the real extent of 
the lesion. When the biopsy is therefore performed, site selection is critical as there 
may be variability in non-uniform lesions and areas with less severe cellular change, 
if sampled, may be interpreted as representative of the lesion as a whole (Epstein et 
al. 2002). This variability may result in erroneous tissue sampling for histological 
diagnosis. In order to combat this and to assess areas of precancerous changes, 
multiple biopsies would need to be taken repeatedly and randomly for analysis which 
would be impractical. It has also been shown that histological grading can be 
subjective and shows limitations in predicting the risk of malignant progression in 
individual patients (Holmstrup et al. 2007). Based on this, there is thus a need for an 
aid to the routine histological method of diagnosis. This would be based on 
molecular characteristics of the tumour, be independent of the subjective histological 
approach to diagnosis and play a role in improving mortality and survival of these 
groups of patients. Precancerous fields are more promising targets for screening 
than early stage tumours, as the time to malignant progression is usually measured 
in years instead of months (Graveland et al. 2013).  
Treatment problems 
Systemic chemotherapy has traditionally been used as palliative therapy for 
advanced stage head and neck cancer and recurrent disease. The management of 
early stage disease is mainly with surgery and radiotherapy with the resultant issues 
around the morbidity (functional disability) associated with surgery which includes 
loss of swallow, speech and airway. Organ preservation is the goal of treatment in 
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order to reduce the morbidity of the disease and this has been greatly enhanced by 
the use of combination therapy (surgery and radiotherapy). The overall 5 year 
survival of the disease however remains low. There is therefore a need for better 
therapies which can be combined with the established modes of therapy to treat this 
disease and improve survival.  
In order to combat the problems associated with the diagnosis and treatment of 
HNSCC patients, two approaches can be employed. First, a molecular based 
approach to the detection of the disease could aid early diagnosis in this group of 
patients. The detection of telomerase activity in saliva of head and neck squamous 
cell cancer patients using a non radioactive PCR based method could serve as a 
simple, non-invasive technique to aid diagnosis. Used in conjunction with histological 
analysis, it could serve as a useful adjunct to diagnosis and treatment providing a 
less invasive and efficient diagnostic medium. It may be used as a molecular marker, 
helping to reduce the morbidity and mortality currently associated with the disease 
and to improve the prognosis. Secondly, the development of novel agents that 
specifically target the biochemistry cancer cells, particularly those pathways 
contributing to the hallmarks of cancer may help to improve survival in head and 
neck cancer patients and survival in cancer patients as a whole. 
 
1.13 Telomerase inhibition 
The telomere/telomerase complex offers a therapeutic window in which cancer cells 
can be efficiently targeted by inhibitors. Telomerase has been a prime target for the 
development of effective therapeutics against cancer as it is expressed inmajority of 
cancer types (Jafri et al. 2016). The main objective of anti-telomerase therapeutics is 
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to selectively induce apoptosis and cell death in cancer cells while minimizing the 
effects on normal cells (Buseman et al. 2012).  
 
The following section describes some of the approaches used to target telomerase 
including the key evidence demonstrating that telomerase is a validated target. 
Validation of telomerase as a cancer inhibitory target 
Telomerase has been demonstrated as one of the key enzymes for human cells to 
acquire immortality (Kim et al 1994). This has been confirmed in the following ways: 
1) Stabilization of mortal human cells through ectopic expression of telomerase 
which facilitates immortalisation - a trait recognised as a crucial step during 
cell transformation (Bodnar et al. 1998; Vaziri and Benchimol. 1998). 
2) Conversion of human fibroblasts or epithelial cells to transformed cancer cells 
which is facilitated by hTERT expression in conjunction with oncogenes (Hahn 
et al. 1999). 
3) Inhibition of telomerase in immortal human cancer cell lines leads to apoptosis 
or senescence (Hahn et al. 1999; Herbert et al. 1999; Zhang et al. 1999; 
Damm et al. 2001). 
Another indication that telomerase is essential for cancer progression has been 
shown in stage ‘4s’ neuroblastoma tumours. Neuroblastoma is a type of 
childhood cancer derived from specialised cells. Neuroblastoma 4s is a ‘special’ 
stage of disseminated neurofibroma found in children less than 1 year. Its 
hallmark is the possibility of spontaneous regression despite large tumour burden 
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(Piefer et al. 2015). Hiyama et al in 1995 studied the regulation of telomere length 
and activity of telomerase in neuroblastoma tumour samples. They found that 
most of the tumours that exhibited high telomerase activity were associated with 
poor prognosis, whereas most of the tumour samples from 4s neuroblastoma had 
low telomerase activity or short telomeres. This suggested that the low 
telomerase activity may be one of the mechanisms responsible for spontaneous 
regression in stage 4s neuroblastoma (Hiyama et al. 1995, Brodeur and Bagatell 
2014; Piefer et al. 2015). 
 
1.14  Telomerase inhibitors 
As previously described, one of the most crucial differences between cancer cells 
and normal cells is that cancer cells have unlimited proliferative capability which they 
acquire via several mechanisms including the activation of telomerase. The potential 
therefore exists for cancer cells to be more critically affected than normal cells by 
any compound that interferes with the telomere/telomerase complex. This provides a 
level of specificity and selectivity. In the early 2000, the telomeres/telomerase 
complex emerged as an attractive possibility for intervention with molecular cancer 
therapeutics and offers multiple possibilities for the development of inhibitors. 
Several strategies for targeting telomere maintenance and telomerase positive 
cancer cells have been explored over the years. The various approaches have been 
reviewed by Sekaran et al (2014) - figure 11, and summarised in table 2.  
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Figure 11 Targeting the overexpression of telomerase in cancer cells (Sekaran et al. 2014)
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Platform Agent References 
Nucleoside analogue reverse 
transcriptase inhibitor  
AZT (azidothymidine) 
 
Strahl and Blackburn 
1996; Melana et al. 
1998 
Non-Nucleoside analogues BIBR1532 Pascolo  et al. 2002 
hTERT and hTERT-telomeric  
DNA heteroduplex 
Aminoglycosides Dominick et al. 2004 
Kaiser et al. 2006 
Transcriptional regulators TMPyP4 Grand et al. 2002 
Post-translational Regulators Protein kinase C 
inhibitors 
Tyrosine kinase 
inhibitors (Imatinib 
mesylate) 
Yu et al. 2001 
 
Uziel et al. 2005 
HSP90 Inhibitors Geldanamycin Villa et al. 2003 
G Quadruplex Stabilizers Telomestatin Tauchi et al. 2003 
Ribozymes Hammerhead ribozymes Lu et al. 2011 
Oligonucleotides and Template 
Agonists 
GRN163L Asai et al. 2003 ; 
Dikmen et al. 2008 ; 
Goldblatt et al. 2009 
RNAi siRNA therapies Li et al. 2005; Noreen et 
al. 2009 
Immunotherapy hTERT derived peptides Liu et al. 2010; Hunger 
et al. 2011 
Gene Delivery Telomelysin Nemunaitis et al. 2010 
 
Table 2 Platforms for targeting the overexpression of telomerase in cancer cells (Sekaran et al. 2014) 
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The first telomerase inhibitors reported were synthetic oligonucleotides which has 
resulted in the lead compound GRN163L (Imetelstat).This is the first telomerase 
inhibitor to enter clinical trials (Roth et al. 2010). GRN163L has been reported to 
inhibit cellular growth in cancer cell lines of diverse origins, including multiple 
myeloma and tumours of the bladder, breast, liver, lung and stomach (Gryaznov et 
al. 2007). Studies in mice carrying liver cancer xenografts showed that GRN163L 
alone inhibited tumour growth, in addition to sensitizing the tumour cells to 
conventional chemotherapy (Djojosubroto et al. 2005). Phase I trials of GRN163L in 
patients with chronic lymphocytic leukaemia, multiple myeloma and solid tumours 
such breast cancer and non-small cell lung cancer have been completed (Bruedigam 
and Lane 2016). Phase II trials to evaluate GRN163L in a maintenance setting 
following treatment with bevacizumab in advanced non-small-cell lung cancer 
(Chiappori et al. 2015) failed to improve progression free survival in this group of 
patients.  Currently, GRN163L is being tested in two clinical trials both currently in 
phase 2: IMbark trial in Myelofibrosis patients, and IMerge trial in Myelodysplastic 
syndrome. Both studies commenced in 2015, patients are currently being enrolled in 
the IMerge trial and in the IMbark trial, enrolment of patients has closed, but 
participants are currently receiving treatment with monitoring.G quadruplex 
stabilizers. 
The compounds used for experiments in this thesis are designed to be G – 
quadruplex stabilizing ligands, therefore, this will be the focus of the thesis. These 
agents are directed at the telomere (Hurley et al. 2000). As mentioned previously, 
the G-rich single stranded telomere overhang has been shown to fold back on itself 
in vitro forming T-loop or G quadruplex structures (Doksani et al. 2013; Palm and de 
Lange. 2008; Lipps and Rhodes. 2009). In order for telomeric DNA extension to 
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occur, telomerase must hybridize to its DNA primer which it is unable to do in the 
presence of G - quadruplex formation. These G quadruplex structures are poor 
substrates for telomerase, and agents that specifically target these structures are 
termed G-quadruplex stabilizing agents.  Zahler et al (1991) demonstrated that 
increasing the stability of G quadruplex structures at telomeres via small molecules 
can negatively disrupt telomere structure and also inhibit telomerase activity (Haider 
et al. 2003; Patel et al. 2007).  These agents stabilise the G–quadruplex structures 
by intercalation and therefore block telomerase during the elongation step. G-
quadruplex stabilizing agents belong to different molecular groups such as 
porphyrins, acridine, anthraquinones and fluorenone based compounds. The first G-
quadruplex ligands explored as telomerase inhibitors were disubstituted 
anthraquinone derivatives (Perry et al. 1999). Other examples include BRACO-19 (9-
[4-(N, N-dimethylaminophenylamino]-3,6-bis(3-pyrrolodinopropionamido acridine) 
(Gowan et al. 2002; Burger et al. 2005) and RHPS4 (3,11 –difluoro-6,8,13-trimethyl-
8H-quino[4,3,2-kl] acridinium methosulphate) (Leonetti et al. 2004; Cookson et al. 
2005). The G-quadruplex ligand, quarfloxin - a fluoroquinolone derivative, has been 
shown to induce apoptosis in adenocarcinoma cells (Drygin et al. 2009). One of the 
hurdles of G – quadruplex targeting has been the poor pharmacokinetic and poor 
pharmacodynamic properties of promising compounds, there are questions about 
safety as they may affect the telomere structure of normal cells as well as numerous 
G-rich regions of the genome (Gunaratnam et al.2007; Patel et al.2007). 
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1.15  Project rationale and aims 
Head and neck squamous cell cancer is a disease with high morbidity and mortality 
especially when detected late as frequently happens. Survival rates have remained 
unchanged in the past three decades. Patients with HNSCC are also at increased 
risk of developing a second primary tumour. A simple non-invasive technique of 
screening and detection would be beneficial in early disease in new patients and in 
patients with a previous history of the disease. This could help reduce the high 
mortality associated with this disease.  
The purpose of this study was firstly to investigate the feasibility of detection of 
telomerase activity in the saliva of patients diagnosed with upper aero-digestive tract 
squamous cell carcinoma using a nonradioactive telomerase PCR-ELISA method. 
This could serve as a diagnostic marker of the disease. Tissues were also collected 
from the same patients in order to test the presence or absence of telomerase using 
immunohistochemical methods. In order to do this, ethics approval was sought from 
the local research and ethics committee. Patients diagnosed with HNSCC were then 
identified, and saliva and tissue samples collected after consents were obtained. 
Saliva samples were also collected from age and sex matched healthy controls. The 
samples were then investigated for telomerase activity. 
As Telomerase has been validated as a target for cancer cell inhibition, the second 
aim of this study was to screen a range of novel compounds with a view to 
identifying effective telomerase inhibitors. Such compounds could offer potential 
therapeutic options which could improve the survival of head and neck cancer 
patients. In order to do this, telomerase activity was first of all demonstrated in a 
range of cancer cell lines and a cell line with high telomerase activity was selected 
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for further study. The potential of the compounds as telomerase inhibitors was 
investigated by determining the effect of these compounds on the telomerase activity 
in cell lysates. The cytotoxic effects of the selected compounds were then 
investigated using telomerase positive cell lines. 
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2 MATERIAL AND METHODS 
The following section describes the materials and methods used for the detection of 
telomerase study, and the inhibition of telomerase study. 
2.1 General materials 
2.1.1 Reagents and disposables 
All chemicals were obtained from Sigma-Aldrich Company Ltd (Poole, Dorset, UK) 
and all disposable plastics were obtained from Corning Incorporated Costar (Schipol 
- Rijk, Netherlands), unless otherwise stated. 
2.1.2 Cells lines 
All cell lines (with the exception of HUVEC cells) were originally purchased from 
American Tissue Culture Collection (ATCC, UK) or from European Collection of Cell 
Cultures (ECACC, UK) and are of human origin. Human umbilical vein endothelial 
cells (HUVEC) were kind gifts from Dr Kirstie Eccles (University of Bradford, UK). 
Table 3 shows the cells and their origin. 
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Cell lines Pathological origin Reference  
A549 Human lung adenocarcinoma Giard et al. 1973 
H157 Human oral squamous cell carcinoma Prime et al. 1990  
H460 Human lung adenocarcinoma Carney et al. 1981 
EJ138 Human bladder carcinoma O’Toole et al. 1983 
HT29 Human colorectal adenocarcinoma Fogh and Orfeo 1977 
A2780 Human ovarian carcinoma Hamilton et al. 1984 
HT1080 Human fibrosarcoma Rasheed et al. 1974 
PC3 Human prostate cancer cell line Kaighn et al. Invest 
Urol 1979 
 
Table 3 Cell lines used in study. 
 
2.1.3 Kits 
Telomerase PCR-ELISA kit was purchased from Roche Diagnostics, Mannheim, 
Germany. RNAqueous®-Micro and RETROscript® Kit were from Ambion – Applied 
Biosystems, Warrington, UK. Taq PCR Core Kit was from Qiagen, Crawley, UK.  
DakoCytomation LSAB 2 System-HRP® kit was purchased from DakoCytomation, 
Glostrup, Denmark. Vectastain ABC kit and DAB peroxidase substrate kit were 
purchased from Vector Laboratories LTD, Peterborough, UK.  
Senescence β – galactosidase staining kit was purchased from New England 
Biolabs (UK) Ltd, Cell Signalling Technology 
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2.2 Materials used in the detection of telomerase study 
2.2.1 Patient and Healthy volunteer data 
The information provided in tables 4 and 5 is simply a list of the samples obtained. 
Details of sample collection, ethical approval and processing of samples can be 
found in section 3. 
Patient number/Sex/Age (yr) Tumour site Tumour stage 
1 / F / 35 
2 / M /44 
3 / M / 56 
4 / F / 63 
5 / M / 51 
6 / M / 59 
7 / F / 57 
8 / M / 82 
9 / M / 70 
10 / M / 67 
11 / M / 45 
12 / M / 62 
13 / M / 69 
14 / M / 48 
Soft palate 
Posterior tongue 
Soft palate 
Lateral tongue 
Posterior tongue 
Lateral tongue 
Base of tongue 
Lateral tongue 
Soft palate 
Lateral tongue 
Anterior tongue 
Soft palate 
Floor of mouth 
Lateral tongue 
T1 
 
T2 
 
T2 
 
T1 
 
T2 
 
T1 
 
T4 
 
T2 
 
T2 
 
T2 
 
T4 
 
T4 
 
T3 
 
T1 
 
 
Table 4 Patient details of 14 patients with squamous cell carcinoma of the oral cavity 
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Healthy Control number/Sex/Age (yr)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 / F / 36 
2 / M /46 
3 / M / 57 
4 / F / 64 
5 / M / 51 
6 / M / 59 
7 / F / 59 
8 / M / 82 
9 / M / 70 
10 / M / 61 
11 / M / 48 
12 / M / 63 
13 / M / 70 
 
Table 5 Healthy volunteers 
 
 
2.2.2 Fluids for mouth wash 
Hartmann’s solution and sodium chloride were obtained from Baxter Healthcare, UK. 
 
2.2.3 Immunohistochemistry materials 
8-well chamber microscopic slide were obtained from Fisher Scientific UK Ltd. Twin 
frosted glass microscope slides were from VWR International Ltd, Poole, UK. Goat 
serum was from Invitrogen, Gibco, NY. Primary antibody (hTERT rabbit monoclonal 
antibody) was from Epitomics, CA, USA.  Secondary antibody (Biotinylated Anti-
Rabbit IgG, made in goat) was from Vector Laboratories Ltd, Peterborough, UK. 
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TBST (Tris-buffered saline + Tween 20) was from Sigma-Aldrich Company Ltd, 
Poole, Dorset, UK). 
2.3 Materials used in inhibition of telomerase study 
2.3.1 Drugs 
Berberine chloride dihydrate, cisplatin, doxorubicin hydrochloride and 5-fluorouracil 
were obtained from Sigma (Poole, Dorset, UK). Berberine chloride was dissolved in 
water. Cisplatin, doxorubicin and 5-fluorouracil were dissolved in DMSO.  
2.3.2 Synthetic compounds 
These compounds were provided by Dr Richard Wheelhouse, School of Pharmacy, 
University of Bradford, UK. The compounds were dissolved in DMSO or sterile 
water. Stock solutions of 1mM or 5mM were prepared and from these, serial dilutions 
were prepared to a varying range of concentrations. The stock solution was stored at 
- 20oC. The compounds were designed to target DNA quadruplexes (Wheelhouse et 
al, 2006), and therefore act as inhibitors of the telomere – telomerase complex.  
34 compounds in all were screened for telomerase inhibition (appendix V and VI). 
The structures of the final 4 compounds selected for further analysis are shown in 
figure 12 below. 
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Figure 12 Structure of novel compounds. The 4 compounds shown above were selected out of 34 
compounds screened for further analysis.  
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2.4 Methods 
2.5 Methods common to the detection of telomerase and the 
inhibition of telomerase studies 
2.5.1 Culture and medium conditions 
A549, H460, EJ138, HT29, A2780 and HT1080 cells were grown in complete RPMI 
1640 medium supplemented with 10% fetal calf serum (FCS), 2mM L-Glutamine and 
1mM sodium pyruvate. H157 cells were incubated in DMEM: HAMS F12 (1:1) 
supplemented with L-glutamine and sodium hydrocortisone succinate (0.5 µg/ml). 
HUVEC cells were incubated in M199-M2154 supplemented with 20% human 
serum, penicillin/streptomycin (100U/100mg/ml) fungizone (2.5µg/ml) and L-
glutamine. All cells were incubated at 37C in a CO2 enriched atmosphere (5%). 
2.5.2 Cell line maintenance 
Cells were routinely maintained as a monolayer culture in T75 flasks and the 
medium (10 ml) was replaced every 3 to 4 days. The cells were passaged when they 
attained approximately 70 to 80% confluence as determined by visual inspection. 
The growth medium was removed, and the cells were washed twice in Hanks 
balanced salt solution (HBSS). The cells were then incubated at 37C in 2ml of 0.25% 
Trypsin-EDTA for 5 min (or until the cells became detached). Complete media (10 
ml) was added and the cell suspension centrifuged for 5 min at 1000g at room 
temperature. The supernatant was discarded, and the cells were re-suspended in 
complete media then re-seeded into new flasks containing fresh medium. Cell were 
discarded after 10 passages and replaced with fresh stocks. 
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2.5.3 Cell counting 
Cells were trypsinised using 0.25% Trypsin-EDTA and re-suspended in fresh 
medium as described above. 10μl of the cell suspension was placed in each 
Neubauer haemocytometer chamber. Cell counts were taken from a total of ten 
grids, 5 counts from each of the haemocytometer chambers using a low power 
objective (x10). The cell concentration was expressed as (mean cell count) x 104 
cells per ml of cell suspension.  
2.5.4 Determination of telomerase activity 
Telomerase activity was assayed using the TeloTAGGG Telomerase PCR ELISA kit. 
The TeloTAGGG Telomerase PCR ELISA is a photometric enzyme immunoassay 
which utilizes the telomeric repeat amplification protocol (TRAP) for the detection of 
telomerase activity. It is an extension of the original method described by Kim et al 
(1994). The assay is based on the principle that telomerase in the cell extract adds 
telomeric repeats to biotin labeled synthetic primers which is amplified by PCR. This 
generates PCR products with telomerase specific 6 nucleotide increments. An 
aliquot of the PCR product is denatured and hybridized to a digoxigenin (DIG) 
labeled, telomeric repeat specific detection probe. The resulting product is 
immobilized via the biotin labeled primer to a streptavidin-coated microplate. The 
immobilized PCR product is then detected with an antibody against digoxigenin (anti-
DIG-POD) that is conjugated to peroxidase. A peroxidase substrate (tetramethyl 
benzidine) is added, which is metabolized by peroxidase to form a coloured reaction 
product. A stop reagent (containing <5% sulfuric acid) is added and the absorbance 
is measured with a microplate (ELISA) reader. Detailed methodology is described 
below. 
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Preparation of cell extracts 
According to the manufacturer’s instructions, 2x105 cells in suspension were used to 
prepare cell extracts. The cells were put into a 0.5ml eppendorf tube (Thistle, UK) 
and centrifuged at 3000g for 10 min in a refrigerated centrifuge at 40C. The 
supernatant was removed, and the cells were re-suspended in phosphate buffered 
saline (PBS) centrifuged at 3000g for 10 min in refrigerated centrifuge at 40C. This 
step was repeated. The cells were then re-suspended in 200µl of lysis reagent 
(provided in the kit), incubated on ice for 30 min, then centrifuged at 16000g for 20 
min at 40C. The supernatant was carefully removed and transferred into a fresh 
0.5ml eppendorf tube. The cell extract was stored at -800C until required or used to 
perform the TRAP reaction immediately. 
Telomeric repeat amplification protocol (TRAP reaction)  
According to the manufacturers’ instructions, 2μl of cell extract was subjected to 
PCR reaction (negative controls were prepared using 2μl of lysis buffer only). Each 
reaction mix consisted of 25μl of reaction mixture (provided in the kit); 2μl of cell 
extract, and sterile deionised water (Sigma-Aldrich, UK) which was added to make 
up a final volume of 50μl. The conditions for PCR amplification were according to the 
manufacturers’ instructions, using a protocol of: primer elongation at 250C for 15 min, 
telomerase inactivation at 940C for 5 min, followed by 30 cycles of amplification 
consisting of denaturation at 940C for 30 s, annealing at 500C for 30 s and extension 
at 720C for 90 s. 
ELISA 
5μl of the PCR product was added to denaturation reagent containing sodium 
hydroxide (<0.5%, provided in the kit). This was incubated at room temperature (15-
250C) for 10 min. Hybridization buffer containing a DIG labeled detection probe 
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(provided in the kit) was added to each sample mixture and mixed thoroughly by 
vortexing. Each sample was transferred into 96-well microplate modules pre-coated 
with streptavidin and post-coated with blocking reagent (provided in the kit). This was 
incubated at 370C on a shaker at 300 rpm for 2h. The hybridization mixture was then 
removed, and the microplate washed 3 times with 250μl of washing buffer (provided 
in the kit). Anti-digoxigenin peroxidase antibody (anti-DIG-POD) was added and the 
microplate incubated at room temperature for 30 min whilst shaking at 300 rpm. The 
solution was then removed, and the microplate washed 5 times with 250μl of 
washing buffer (provided in the kit). TMB substrate (tetramethyl benzidine) was 
added, and the microplate incubated at room temperature for 15 min, whilst shaking 
at 300 rpm. Stop reagent was then added, and the absorbance measured using an 
ELISA microplate reader at 450nm (with a reference wavelength of 690nm), within 
30 min. Samples are regarded as positive for telomerase activity if the difference in 
absorbance between the sample absorbance and negative control absorbance was 
higher than 0.2.  
2.5.5 Measurement of protein concentration using the Bradford assay 
The total protein concentration of the cell lysates was determined by the Bradford 
assay. The assay is based on the ability of Coomassie brilliant blue to combine with 
proteins to give a dye-protein complex with an absorption maximum of 595nm 
(Bradford 1976). The 1x Bradford reagent (Sigma Aldrich, Dorset, UK) was pre-
warmed to ambient temperature prior to use. Bovine Serum Albumin (BSA, Sigma 
Aldrich, Dorset, UK) was used as the standard to determine the linear range of the 
assay (a serial dilution of BSA was prepared in double distilled water at a range of 
1mg/ml to 0.0625mg/ml). 100μl of each BSA dilution was mixed with 3ml of Bradford 
reagent by vortexing. 100μl of deionised water was also mixed with 3ml of Bradford 
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reagent and this served as the blank that was used to ‘zero’ the spectrophotometer. 
Each mixture was incubated at room temperature for at least 5 min (but no longer 
than 1h). Samples were then transferred into clean disposable cuvettes (Fisher 
Scientific, UK) and absorbance measured at 595nm using a Cary 50 Bio UV–Visible 
Spectrophotometer (Varian Australia Pty Ltd, Australia). Each reading was 
performed in triplicate. A standard curve was constructed by plotting mean 
absorbance against BSA concentration as seen in figure 13. Dilutions of cells lysates 
were then prepared in distilled water, 100μl of which was added to 3ml of Bradford 
reagent and tested as described above. The protein concentration of the cell lysate 
was determined by comparing absorbance values against the standard curve. If the 
absorbance of the samples fell outside the linear range of the calibration curve, the 
samples were again diluted to obtain values within the linear range. The protein 
concentration of the original sample was then determined by multiplying the 
calculated concentration by the dilution factor. Figure 13 shows a typical standard 
curve obtained. 
 
 
63 
 
 
 
Figure 13 Representative example of a Bradford assay standard curve 
 
2.5.6 Sensitivity of the TeloTAGGG Telomerase PCR ELISA kit 
In order to determine the sensitivity of the kit, cell lysates produced from a cell line 
with known telomerase activity (A549) was serially diluted with lysis buffer and then 
assayed for telomerase activity. Varying concentrations of cells from a cell 
suspension were also added to saliva samples that had been collected from healthy 
volunteers as previously described. The samples were then centrifuged as described 
previously and the pellets were assessed for telomerase activity. The absorbance 
values obtained were plotted against the protein concentration of the cell lysate. 
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2.6 Methods specific to detection of telomerase activity 
Ethics approval for study 
Ethics approval was sought for the study. Approval was obtained from the Local 
Research and Ethics Committee (LREC) and the Research and Development 
Department of the Bradford Royal Infirmary. Approval was obtained for the collection 
and analysis of saliva samples and tumour tissue from patients diagnosed with head 
and neck squamous cell carcinoma and saliva samples from healthy controls 
(Appendix I). The period during which clinical data and samples collected spanned 
from 2005 – 2007. 
Protocol for recruitment 
Following ethics approval, patients newly diagnosed with HNSCC were identified in 
outpatients’ clinic prior to surgery and recruited into the study. Information about the 
study was provided to the patients and their consent was sought prior to samples 
being collected (Appendix II – IV).  
 
2.6.1 Collection of samples 
Saliva samples were collected from recruited patients and healthy controls by asking 
individuals to gargle with either sodium lactate solution [Hartmann’s Solution] or 
0.9% sodium chloride solution (Baxter Healthcare Ltd, England). This was in the 
form of a mouth rinse. Samples were collected at least 2h after the patient ingested 
any food or drink. The solution was collected in a sterile tube, centrifuged at 1500g 
for 5 min and a pellet was obtained which was immediately frozen on dry ice. The 
pellet was stored at -800C until required (as described in section 1 using the A549 
cell suspension). Formalin fixed, wax embedded specimens of the patient tissue 
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were obtained from the pathology department at Bradford Royal Infirmary. 
Histological stage was obtained from histology reports prepared by consultant 
pathologists in Bradford Teaching Hospitals NHS Trust. 
2.6.2 Determination of best method of collection and storage of saliva samples  
To determine the best method to use for collecting samples, healthy individuals were 
asked to gargle with either 3ml or 10ml of either 0.9% sodium chloride solution or 
Hartmann’s solution. For the 3ml sample, a further 15ml of solution was added to the 
sample. Cells from a cell suspension of cell lines with known telomerase activity 
(freshly prepared 2x105 cells from A549 cultures) were added to each sample, and 
centrifuged at 1500g for 5 min to obtain a pellet which was tested for telomerase 
activity 
2.6.3 Determination of effect of saliva and collection fluid on the detection of 
telomerase activity 
To ensure that the constituents of normal saliva did not affect the detection of 
telomerase activity (and also to mimic the saliva environment), healthy individuals 
with no past history of HNSCC were asked to gargle with either 0.9% sodium 
chloride solution or Hartmann’s Solution. Cells from a cell suspension of a cell line 
with known telomerase activity (2x105 cells from A549 cultures) were added to the 
saliva samples, centrifuged and stored at -800C as described previously. 
2.6.4 Preparation of saliva smears 
Saliva samples were collected, and a cell pellet produced as described previously. 
The cells were smeared on clean slides using a disposable pipette. The slides were 
fixed immediately in 95% ethyl alcohol for 30 min or air-dried. 
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2.6.5 Haematoxylin and Eosin staining 
In this widely used histological stain, the heamatoxylin component stains the cell 
nuclei blue black, and the eosin stains the cell cytoplasm red/pink. Haematoxylin and 
Eosin staining was performed as described below in table 6. 
Step  Process Time 
1 Haematoxylin 10 minutes 
2 Wash in running tap water Briefly 
3 Acid alcohol 5 seconds 
4 Wash in running tap water Briefly 
5 Scott’s tap water 
substuitute 
1.5 minutes 
6 1% aqueous eosin 1 minute 
7 Wash in running tap water Briefly 
8 Drain slides 1 minute 
9 Absolute ethanol 1 minute 
10 Absolute ethanol 3 minutes 
11 50%xylene ethanol 3 minutes 
12 Xylene 3 minutes 
13 Xylene 5 minutes 
 Mount slide using DPX  
 
Table 6 Process of haematoxylin and eosin staining  
 
2.6.6 Trypan blue viability 
To determine cell viability in saliva samples, 0.4% Trypan blue stain was used. This 
method is based on the principle that live cells are able to exclude the dye and dead 
cells take up the dye. Approximately 100µl of saliva sample (it is an approximate 
volume due to the viscous nature of some saliva samples) mixed with same amount 
of trypan blue solution 0.4% (Sigma Aldrich, Dorset, UK) was placed in a Neubauer 
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haemocytometer chamber. This was then viewed using a low power objective (x10) 
to determine the uptake of tryphan blue, indicating viability of the cells. 
Immunohistochemistry/immunocytochemistry 
Immunocytochemistry and immunohistochemistry are techniques used to detect 
cellular antigens (immunocytochemistry) or tissues sections (immunohistochemistry). 
This is achieved by the use of specific antigen/antibody interactions that culminate in 
the attachment of a marker to the antigen. They allow reproducible and consistent 
demonstration of specific antigens with the minimum of background staining whilst 
preserving the integrity of the cellular/tissue architecture. The antigen/antibody 
complexes can then be visualised via light microscopy. hTERT protein is 
heterogeneously expressed in nucleoli of some normal and most cancer tissues and 
immunocytochemical and immunohistochemical staining was used to detect hTERT 
protein expression in cultured cells and tissue sections as described below. 
2.6.7 Immunocytochemistry 
Cell culture on microscopic slides 
H157, an oral squamous cell carcinoma cell line shown to be telomerase positive 
and HUVEC cells, shown to be telomerase negative were used for 
immunocytochemistry. A cell count was performed and 500μl of the cell suspension 
at a density of 1 x 104 cells/ml (5000 cells) in medium DMEM for H157 cells and 
M199-M2154 medium for HUVEC cells was seeded into each well of a sterile eight - 
well chamber microscopic slide (Lab-Tek II chamber slide system, Fisher Scientific 
UK Ltd). The cells were incubated at 37C in a CO2 enriched atmosphere of 5% CO2. 
The media was changed after 24h in order to allow the cells to attach. After the cells 
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attained 60% confluence, the media was aspirated from the chamber slides and the 
cells were now ready for fixing as described below. 
Immunocytochemistry on cultured cells 
All procedures were carried out at room temperature, unless stated otherwise. Cells 
were cultured on multi – well microscopic slides as previously described.  
Preparation of blocking sera 
In order to make 10% goat serum, 1ml of freshly thawed goat serum (Invitrogen, 
Gibco, NY) was added to 9ml of PBS solution. The mixture was vortexed and then 
transferred to 1.5ml Eppendorf tubes. The Eppendorf tubes were then placed in a 
microcentrifuge and centrifuged at 1300g for 5 min to remove any particulate 
material. The resulting serum solution was stored at 4C and used for the blocking 
step. To make the 1% goat serum, 100μl of goat serum was added to 9.9ml of PBS 
solution. This was then vortexed and used to dilute the primary antibodies to the 
required concentration.  
Preparation of the primary antibodies 
The primary antibody (hTERT rabbit monoclonal antibody, Epitomics, CA, USA) was 
made up into the required dilutions (1:50, 1:100 and 1:200), using 1% goat serum. 
The diluted primary antibody was centrifuged for 5 min at 1300g to remove 
particulates and stored at 40C until needed. 
Cell fixation 
The culture medium was gently aspirated from each well and the cells were placed in 
ice-cold methanol at -200C for 10 min. The cells were then rehydrated in PBS for 2 
min. 
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Blocking 
A blocking solution consisting of 10% goat serum was prepared in PBS as previously 
described. 200μl of the blocking solution was added to each well. The slides were 
then incubated in a covered square dish for 1h at room temperature. 
Staining 
After 1 h incubation in the blocking solution, each well was drained carefully of the 
goat serum and 100μl of the appropriately diluted primary antibody (1:50, 1:100 and 
1:200) was added to 2 wells. 100μl of goat serum only was added a further 2 wells to 
serve as the negative control. The slides were incubated with the primary antibody 
overnight at 40C. The next day, the cells were washed with 200μl of PBS for 5 min 
and this was repeated twice. The DakoCytomation LSAB 2 System-HRP® kit 
(DakoCytomation, Glostrup, Denmark) was used for staining. Secondary antibody 
(100μl obtained from the kit), was added to each chamber and incubated for 15 min 
at room temperature. The secondary antibody was aspirated, and the cells were then 
washed with 200μl PBS for 5 min and this was repeated twice. Streptavidin - 
peroxidise solution (100μl from kit) was added to each well and incubated for a 
further 20 min at room temperature. The streptavidin - peroxidise solution was 
aspirated, and the cells were then washed with 200μl of PBS for 5 min and this was 
repeated twice. 200μl of distilled water was added to each well and incubated for 2 
min. The distilled water was aspirated and 200μl of DAB substrate - chromogen 
solution (provided in the kit) was added to each well and incubated for 10 min. Each 
chamber was then washed 3 times with 200μl of distilled water. The chambers were 
then carefully removed from the slide and the cells were mounted.  
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Mounting the microscopic slides 
The cells were mounted using Glycergel® mounting medium (DakoCytomation, 
Glostrup, Denmark). The glycergel was warmed in a 400C water bath to liquefy and a 
small amount was then placed on the centre of a 22 x 50mm coverslip (VWR 
International, Poole, UK) and carefully placed on the wet slide. The slide was then 
left to set for 90 min. 
2.6.8 Immunohistochemistry 
A549 xenografts were used for immunohistochemistry as A549 cells have been 
shown to have telomerase activity (see figure 14 below). A549 xenografts and 
formalin fixed/wax embedded specimens of patient tissue samples were used. The 
A549 xenografts were derived from subcutaneously grown tumours in NCR/Nu mice 
that had been surgically excised from mice under anaesthesia.  All procedures were 
carried out by ICT staff and conducted under United Kingdom Co-ordinating 
Committee on Cancer Research (UKCCR) guidelines (1998) and Home Office 
project licence (40/2585). The formalin fixed/wax embedded specimens of the 
patient tissue samples were obtained from the pathology department at Bradford 
Royal Infirmary. Tissue samples were not available for all patients in the study.  
 
Preparation of A549 xenograft 
The freshly excised A549 xenograft tumour samples were immersed in 10% formalin 
in 0.01M phosphate buffered saline for 24 h in order to achieve tissue fixation. The 
samples were then loaded onto histology biopsy cassettes and processed in an 
automatic tissue processor using the following processing cycles: 70% ethanol for 60 
min, 80% ethanol for 60 min, 95% ethanol for 60 min, 100 % ethanol for 60 min, 
fresh 100% ethanol for 60 min, fresh 100% ethanol for 120 min, 100% xylene for 60 
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min, fresh 100% xylene for 60 min, fresh 100% xylene for 120 min, paraffin wax for 
150 min and then fresh paraffin wax for a further 150 min. The fixed tissue samples 
were then embedded in paraffin blocks. 
Preparation of tissue sections 
Formalin fixed paraffin embedded tissue blocks of A549 xenografts and that of 
patients were cooled for a minimum of 20 min in the -200C freezer. The blocks were 
then cut using a microtome into 5 micron sections. Tissue sections were mounted 
onto BDH 1.2 mm twin frosted slides pre-coated with 3-amino-propyl-triethoxy-silane 
(APES) via a warm water bath at 480C and left on a heating plate overnight to dry. 
Deparaffinization and Rehydration 
In order to soften the wax, the slides were placed in the oven at 650C for 1h. The 
slides were then deparaffinised and hydrated as described below in table 7. 
Step Process Time 
1 Xylene x2 5 min 
2 Absolute ethanol x2 5 min 
3 95% ethanol 5 min 
4 70% ethanol 5 min 
5 50 % ethanol 5 min 
6 30% ethanol 5 min 
7 water 5 min on shaker 
8 TBST 5 min on shaker 
 
Table 7 Process of deparaffinisation and hydration of slides 
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Antigen retrieval  
Antigen retrieval solution (citric acid buffer, pH 6.0) was prepared using citric acid 
and double distilled water (10mM citric acid + 0.05% Tween + double distilled water). 
Two methods of antigen retrieval were investigated. The first method was using the 
microwave and the second method was using the oven. Different concentrations of 
primary antibody were also used in both methods (1:200, 1:100 and 1:50). 1:50 
dilution was the primary antibody concentration selected for the patient tissue 
samples as preliminary studies demonstrated that this gave the best degree of 
staining. 
 
Microwave method of antigen retrieval 
In order to determine the effect of microwaving on the antigen retrieval process, 
different methods of antigen retrieval using the microwave was performed: a) 20 min 
microwave, b) 10 min microwave, c) no microwave. The slides were immersed in a 
dish containing antigen retrieval solution and heated in the microwave for 10 or 20 
min. Two slides were immersed in the antigen retrieval solution but were not placed 
in the microwave (no microwave). The slides were then left in the antigen retrieval 
solution to cool for 30 min.  
Oven method of antigen retrieval 
Antigen retrieval solution was warmed up to 900C in the oven and the slides were 
immersed in the antigen retrieval solution for 40 min. The slides were then cooled 
quickly in running water for 10 min. 
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Staining 
Slides were washed with TBST (Tris-buffered saline + Tween 20, Sigma-Aldrich 
Company Ltd, Poole, Dorset, UK) for 10 min. Endogenase peroxidase was 
inactivated by adding 1% (v/v) hydrogen peroxide to each section for 30 min. Slides 
were then washed 3 times with TBST (for 3 mins per wash). Excess TBST was 
carefully blotted off with tissue avoiding touching the sections, and the sections were 
then encircled using a PAP pen (DAKO Ltd, Cambridgeshire, UK) in order to create 
a hydrophobic wall around the sections. The 1% and 10% goat serum were prepared 
as previously described. 200μl of 10% goat serum was used as blocking solution, 
added to each section, and this was incubated for 1h. The primary antibody (hTERT 
rabbit monoclonal antibody, Epitomics, CA, USA) was prepared by making up 1:50, 
1:100 and 1:200 dilutions with 1% goat serum (as described previously). After 1h 
incubation with 10% goat serum, each slide was drained carefully of the goat serum 
and 100μl of primary antibody for each dilution was added to a section on the slides. 
100μl of goat serum was also added to a section as the negative control. The slides 
were incubated with the primary antibody overnight at 400C. 
The next day, the slides were washed in distilled water, and then washed for 3 min 
each, 3 times with TBST. Secondary antibody (Biotinylated Anti-Rabbit IgG, made in 
goat, Vector Laboratories LTD, Peterborough, UK) was prepared with 1% goat 
serum making up a 1:200 dilution. This was applied to each section and incubated at 
room temperature for 1h. The secondary antibody was then removed, and the slides 
washed for 3 min, 3 times in TBST. The Vectastain® ABC reagent (Vectastain 
Avidin: Biotiylated enzyme complex, ABC kit, Vector Laboratories LTD, 
Peterborough, UK) was freshly prepared according to manufacturer’s instructions by 
adding 1 drop of solution A and 1 drop of solution B to 5mls of PBS. This was left to 
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stand for 30 min. The ABC reagent was then added to each section and incubated 
for 30 min at room temperature. The ABC reagent was removed, and the slides 
washed in distilled water. The slides were then washed for 3 min, 3 times in TBST. 
DAB peroxidase substrate (DAB peroxidase substrate kit, Vector Laboratories LTD, 
Peterborough, UK) was freshly prepared according to manufacturer’s instructions, by 
adding 1 drop of buffer stock, 2 drops of DAB stock solution and 2 drops of H2O2 
stock solution into 2.5ml distilled H2O. This was then added to each section for 5 min 
at room temperature until colour development. Each slide was rinsed with distilled 
water and then rinsed with tap water for 5 min.  
Counterstaining 
The sections were counterstained with Harris haematoxylin. The slides were placed 
in haematoxylin for 20 s and immediately washed in running tap water for 1min. The 
sections were then placed in Scott’s tap water for 1 min. The slides were dehydrated 
as described below in table 8. 
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Step  Process Time 
1 70% ethanol 3 min 
2 90% ethanol 3 min 
3 Absolute ethanol 3 min 
4 Absolute ethanol 3 min 
5 50% xylene/ethanol 3 min 
6 Xylene 3 min 
7 Xylene 5 min 
 
Table 8 Process of dehydration of slides 
 
 
Mounting of slides 
The slides were then mounted using DPX® mounting medium (VWR International, 
Poole, UK). After dehydration, the slides were removed from the xylene one by one, 
the edges were dried, a small drop of DPX was placed on a 22 x 50mm coverslip 
and this was carefully applied to the slide pressing gently to remove air bubbles. The 
slides were left flat to set for 1h. The staining was observed under a light 
microscope. 
76 
 
2.7 Methods specific to the inhibition of telomerase study 
2.7.1  Methodology for telomerase inhibition by compounds 
Berberine chloride has been shown to be a moderate inhibitor of telomerase 
(Naasani et al 1999). On this basis it was selected as a positive control to develop an 
experimental technique for screening novel compounds. In order to assess the ability 
of berberine chloride to inhibit telomerase, an initial stock concentration of 1mM was 
prepared with water. This was added to the cell lysates (freshly produced from 2x105 
cells), to make final concentrations of 200, 20, 2 and 0.2µM of berberine chloride, 
and each lysate was then incubated at 370C for 2h. The 2h time period was chosen 
based on the results of the stability of the telomerase enzyme at 37 0C with time 
(section 4.4.1). The absorbance values obtained were plotted against the berberine 
chloride concentrations. The control was cell lysate with an equal volume of water as 
drug volume, incubated at 370C for 2h. After incubation, 2µl of drug/lysate mixture 
was added to the PCR reaction mixture and subjected to PCR/ELISA as described in 
section 3.1.4.  Other established cytotoxic drugs, (doxorubicin, 5 fluorouracil, and 
Cisplatin) were also assessed with the above methodology. The novel compounds 
were then screened using the above methodology. 
2.7.2 Evaluation of selected compounds as non-specific inhibitors of 
telomerase 
In order to ensure that the inhibition detected was a result of specific telomerase 
inhibition rather than a false positive/nonspecific inhibition of Taq polymerase, each 
compound was subjected to PCR reaction/agarose gel electrophoresis, to detect the 
presence or absence of β actin. The absence of β actin suggested the compound 
inhibited Taq polymerase (and as such, the PCR reaction). Detailed methodology is 
described below. 
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RNA extraction 
Using A549 cells, a cell pellet was prepared as described in section 3.1.4. Using the 
RNA extraction kit (RNAqueous®-Micro, Ambion – Applied Biosystems, Warrington, 
UK), the cells were lysed by adding 100μl of lysis solution. 50μl of 100% ethanol was 
added to the lysate and vortexed briefly. The lysate/ethanol mixture was then loaded 
onto a MicroFiltre Cartridge Assembly (consisting of filter and collection tube, from 
kit) and with the cap on, was centrifuged at 40C for 1 min at 16000g. This allows the 
entire sample to pass through the filter into the collection tube and the solution from 
the tube discarded. The RNA binds to the filter in the microfilter cartridge.  The filter 
was washed 3 times with 180μl of wash solution (working solution mixed with 
ethanol, from kit) by adding the wash solution to the filter and centrifuged as above. 
The contents of the collection tube were discarded each time. The microfiltre was 
transferred into a microelution tube (from kit).10μl of elution solution (provided with 
kit and preheated to 750C), was added to the filter, this was left to sit for 1 minute at 
room temperature, then centrifuged at 40C for 1 min at 16000g to elute the RNA from 
the filter. DNA contamination was removed from the eluate by adding 2μl of 10X 
DNase buffer and 1μl of DNase I (provided with kit). This was placed in a water bath 
for 30 min at 370C. The DNase was inactivated by heating the tube at 750C for 15 
min. 
RNA analysis 
The quantity and yield of RNA extraction was measured using a Cary 50 Bio UV–
Visible spectrophotometer (Varian Australia Pty Ltd, Australia). This was determined 
by diluting 2µl of RNA in 198µl of distilled water. The distilled water alone was used 
as the blank sample. The RNA sample absorbance was measured at the ultraviolet 
wavelengths of 260nm (A260) and 280nm (A280). An A260 of 1 is equivalent to 40 µg/ml 
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and the RNA quantity (μg/ml) was calculated by using the absorbance value at 
260nm, using the following formula  
[Absorbance260 X 40 X dilution factor (of RNA)]. 
The ratio of the sample absorbance at 260nm (absorbance for RNA) and 280nm 
(absorbance for proteins) was calculated and ratios of 1.7 - 2.1 are essentially free of 
protein contamination.  
cDNA synthesis (reverse transcription)  
Reverse transcription of the RNA was performed using the RETROscript® Kit 
(RNAqueous®-Micro, Ambion – Applied Biosystems, Warrington, UK). The RNA was 
first of all denatured with heat by adding 2μl of RNA to 2μl of oligo (dT) and 8μl of 
nuclease-free water to make a total volume of 12μl (2 tubes of above solution were 
prepared). Each tube was incubated at 750C for 3 min, and then cooled on ice. A 
reaction mixture containing 2μl of 10X buffer, 4μl of dNTP mix (premixed aqueous 
solution of dATP, dCTP, dGTP, dTTP at a final concentration of 10mM), 1μl of 
RNase inhibitor, 1μl of MMLV- RT and 12μl of RNA/oligo(dT) mixture made up to 
20μl with nuclease free water and labelled as tube 1. Tube 2 contained the above 
without MMLV-RT. This served as a control to detect DNA contamination in the 
reaction. Each tube was incubated at 430C for 1h. The tubes were then incubated at 
920C for 10 min in order to inactivate the reverse transcriptase. The cDNA product 
was stored at -200C until needed. 
Amplification of β actin cDNA by Polymerase chain reaction (PCR) 
The PCR kit used was Taq PCR Core Kit (Qiagen, Crawley, UK). β actin primers 
were supplied by MWG Biotech, Ebersberg, Germany. The specificity of primers was 
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checked via a BLAST search (NCBI website) and was shown to be specific to β 
actin. The primers used were as follows: 
Forward       5’ – CCA-CGA-AAC-TAC-CTT-CAA-CTC-C – 3’  
Reverse       5’ – TCA-TAC-TCC-TGC-TTG-CTG-ATC-C – 3’ 
Each primer was made up to 10μM stock in distilled water and added to the PCR 
reaction mix to give a final concentration of 0.2μM. The primer stock solution was 
stored at -200C. 
To a sterile PCR tube (AXYGEN Scientific, CA) on ice, 1µl of dNTP stock solution, 
1µl of each primer (10µM of reverse and forward primers), 5µl of Taq PCR 10X 
buffer, 0.25µl of Taq DNA Polymerase, 1µl of cDNA and sterile double distilled water 
were added to make up a 50µl reaction mixture. First, a reaction mix (without cDNA) 
was prepared to avoid tube to tube inconsistency (master mix). For the reaction mix 
containing the novel compounds, each compound was made up to 1mM stock (using 
either DMSO or water) and added to the PCR mix to give a final concentration of 
200μΜ. The PCR conditions used were: initial denaturation at 94 0C for 1 min, 
denaturation at 940C for 30s, annealing at 600C for 45s, elongation at 720C for 30s, 
final elongation at 720C for 5 min and cooling at 150C. The reaction was carried out 
for 35 cycles. 
PCR controls used included: 2 negative controls – one without RT (reverse 
transcriptase) and the other without cDNA; and a positive control with added cDNA. 
Each 1µl of each PCR product was added to 2µl of loading dye (Sigma-Aldrich, 
Dorset, UK) and run in parallel with a 1kb plus DNA ladder (Invitrogen, UK) on a 2% 
agarose gel (agarose in 0.5X Tris-Borate-EDTA-buffer) stained with 0.5 µg/ml 
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ethidium bromide (sigma-Aldrich, Dorset, UK) at 100V for 1 hour. The gel was then 
scanned using Multimager Fluor-S (Bio-Rad, Hertfordshire, UK). 
2.7.3 The chemosensitivity assay (MTT) 
The MTT assay was used to determine cell survival. This assay relies upon 
measuring the cellular reduction of a yellow, water soluble tetrazolium salt, MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) via succinate-dependent 
conversion by mitochondrial enzymes to a purple, water insoluble formazan product 
that can be detected at visible wave length on a multiwell scanning 
spectrophotometer following dissolution in an organic solvent (Mosmann 1983). 
Validity of the MTT assay 
The validity of the MTT assay was assessed by examining the linear relationship 
between cell number and absorbance values. Serial cell dilutions (in a total volume 
of 200µl of media), containing different concentrations of cells were seeded into 96-
well plates (8 wells per dilution). One lane (with 8 wells) was prepared with just 
media (200µl/well) and no cells as a blank. This was followed by the addition of 20μl 
volume of MTT (5mg/ml) to each well. The plates were incubated in the dark for 4h 
at 370C. The supernatant was then carefully removed and discarded leaving the 
reduced formazan crystals at the bottom of the wells. 150μl of DMSO was added to 
each well to dissolve the crystals. The absorbance was read immediately at 540nm 
using a Labsystems Multiscan Plus Spectrophotometer (Labsystems group, UK). 
The mean absorbance value was calculated for each dilution and the blank value 
was subtracted from each calculated mean absorbance. The adjusted mean 
absorbance was then plotted against the cell numbers. A linear regression was 
calculated to check the linear relationship between absorbance and cell number. 
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Chemosensitivity measurements 
1000 cells per well were seeded into 96-well plates, preparing lanes 2 to 12. Lane 1 
was left as a blank (with media and no cells). For the HUVEC cells, 20000 cells 
(2x104 cells) per well were seeded into 96-well plates. The cells were then incubated 
at 370C overnight to attach. The media was carefully removed and replaced with 
fresh media containing a range of concentrations of selected compounds serially 
diluted (except lane 1 which was left with media alone and lane 2 (control) with cells 
in media but no compound). The cells in lanes 3 to 12 were exposed to compounds 
for 2h and 96h. After 2h incubation at 370C, the cells were washed twice with HBSS, 
fresh media was added, and the cells incubated for a further 96h at 370C. The cells 
exposed to compounds for 96h were left undisturbed. Following incubation, cell 
survival was determined by using the MTT assay as described previously. The mean 
value was calculated for 8 absorbance measurements per drug dilution lane (and 
control lane) and the mean of the blank measurements subtracted from each mean 
absorbance value. The adjusted absorbance values were used to calculate the 
percentage cell survival using the control values as 100% cell survival as follows: 
% survival = (Absorbance of treated cells/Absorbance of control cells) x 100 
This % survival was plotted against the drug concentration range and IC50 
(concentration required to kill 50% of cells) was determined. 
2.7.4 Evaluation of the mechanism of telomerase inhibition by the selected 
compounds 
As described previously, chromosomal ends are protected by the telomere which 
forms a cap at the end of the chromosomes. As well as the effect on the elongation 
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of the telomere ends, telomerase also stabilizes the telomere through its additional 
stabilization of the telomere cap (Blasco 2002, Masutomi et al 2003, Sung et al 
2005). The differences in telomerase activity and telomere dynamics between cancer 
and normal cells and also the telomere/telomerase complex offers multiple 
possibilities for inhibition. Further evaluation of the mechanism of action of the 
selected compounds on the telomere/telomerase activity was investigated by looking 
at the ability of compounds to induce cellular senescence using the senescence 
assay. Cells lines selected for this study were the PC3 and A549 cell lines. 
2.7.5 Senescence associated β galactosidase staining 
Senesecence is an arrested state in which the cell remains viable but display altered 
patterns of gene and protein expression. Interference with telomerase architecture 
has been shown to evoke cell cycle arrest and senescence (Leonetti et al, 2004). 
 
Senescence assay 
The senescence assay was used to determine if the selected compounds which 
showed telomerase inhibition exerted growth inhibitory effects on cancer cells. A 
commonly used marker for senescence in vitro is the appearance of senescence 
associated β – galactosidase activity. Senescence was assayed using the 
senescence β – galactosidase staining kit (New England Biolabs (UK) Ltd, Cell 
signalling technology), based on a procedure first described by Dimri et al in 1995. 
The assay relies on the ability of senescent cells to express β galactosidase and this 
can be detected in single cells by X gal which forms a local blue precipitate upon 
cleavage. According to the manufacturer’s instructions, cells were seeded into 6-well 
plates and incubated at 370C overnight to attach. The growth medium was then 
carefully removed from the cells and each well washed with 2ml of 1X PBS. The 
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cells were then fixed with 1ml of 1X fixative solution for 15 min at room temperature. 
The staining solution was prepared using 20mg/ml of X-gal in DMF, staining solution, 
staining supplement A and B (all provided in the kit). After 15 min, the cells were 
washed twice with 2ml of 1X PBS and then 1 ml of staining solution was added to 
each well and incubated overnight at 370C. Development of blue colour was 
assessed under a light microscope. The plates were overlaid with 70% glycerol and 
stored at 40C. 
 
Plating of cells 
In order to determine the best concentration of cells to use for the senescence 
assay, 10000 cells, 1000 cells and 100 cells were seeded into 6 well plates and 
incubated for 5, 10 and 15 days each. On day 5, the plate was read for the 5 day 
incubation and the media was changed for the 10 day incubation. On day 10, the 
plate was read for the 10 day incubation and the media was changed for the15 day 
incubation. On day 15, the plate was read for 15 day incubation.1000 cells per well 
was the cell number selected for plating as preliminary studies demonstrated that 
this gave the best cell confluence (data not shown).  
 
Determination of minimally toxic drug concentrations 
Chemosensitivity measurements using the MTT assay were made to determine sub-
toxic doses (IC 10 - doses at which 90% of the cells are viable) of the compounds. 
10 fold dilutions of the sub-toxic doses of the compounds were prepared and then 
added to the cells in order to demonstrate the senescence effect.  
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Methodology for β galactosidase staining following drug exposure.  
In vitro studies have shown that arsenic induces DNA and chromosome damage 
(Zhang et al, 1999; Chou et al 2001). On this basis, it was selected as a control to 
exhibit senescence. 1000 cells per well were seeded into 6-well plates and incubated 
at 370C overnight to attach. The media was carefully removed and replaced with 
fresh media containing 10 fold dilutions of the sub-toxic doses of arsenic and the 
compounds (well 1 was left with media alone to serve as a control). The media was 
replaced every five days with fresh media containing the same concentrations of 
compounds (except well 1 which was replaced with media alone). The cells were 
exposed to arsenic and the compounds for 5, 10 and 15 days at 370C, after which β 
galactosidase expression was assessed as described above. 
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3 RESULTS 
Telomerase assay 
3.1 Detection of telomerase activity 
Telomerase activity was initially determined using a known telomerase positive A549 
cell line. A549 cells were counted and lysates were produced from 2 x 105 cells 
which were then assayed for telomerase activity using the telomerase PCR ELISA 
kit. Telomerase activity is represented by the absorbance value obtained in this 
assay. Figure 14 shows a representative result. The A549 cell line gave high 
absorbance values indicating the presence of telomerase activity, comparable to the 
positive control provided in the kit. In many instances there were day to day 
variations in the absolute absorbance values obtained in each experiment 
(depending on the age of the kit) and therefore the results shown in figure 14 below 
and in other figures are from individual experiments. 
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Figure 14 A, B Telomerase activity in A549 cells. Results show absorbance values from duplicate 
determinations in single experiments. There were variations in absolute absorbance values obtained in 
each experiment as this depended on the age of the kit.  POS represents positive control (cell extract) and 
NEG represents negative control (lysis buffer) as supplied by the manufacturers of the kit.  
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3.2 Sensitivity of telomerase PCR ELISA kit 
To investigate the quantitative nature and the sensitivity of the telomerase assay 
using the telomerase PCR ELISA kit, telomerase activity was measured in: 
1. A549 cell lysates produced from serial dilutions of a known number of cells 
(Figure 15).  
2. A549 cell lysates produced from an initial suspension with a known number of 
cells which were then serially diluted with lysis buffer (figure 16). The 
relationship between the protein content of the serially diluted cell lysates and 
the absorbance obtained in the telomerase assay of these lysates was also 
investigated (Figure 17). 
Serial dilution of cells 
A549 cells were counted and 2 x 105 cells in suspension were serially diluted with 
media to give varying cell numbers per ml. Each ml of cell suspension was then 
centrifuged, and the cell pellets were lysed. 2µl volume of each lysate (see section 
3.1.4) was assayed for telomerase activity in 3 separate experiments using lysates 
from different cell counts for each experiment. The results show a reduction in 
absorbance values as the cell counts reduced (Figure 15 A, B, C), however, when 
the cell counts fell below 1000 cells/ml, there was a sharp drop and inconsistency in 
the absorbance values detected  
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Figure 15 A, B & C are three independent experiments showing the relationship between cell 
concentration (used to prepare the lysate) and absorbance in the telomerase assay. 2µl of each lysate was 
used in the PCR reaction. Results show absorbance values from single determinations in each experiment.  
 
Serial dilution of cell lysate 
To investigate the effect of serial dilution of the cell lysate (and protein 
concentration), a cell lysate produced from 2 x 105 A549 cells, of known protein 
concentration (0.8μg/µl), was diluted with lysis buffer. 10µl volumes of lysate was 
serially diluted with 10µl of lysis buffer (with corresponding dilution of the protein 
concentration). 2µl of the diluted lysates was then used for the PCR reaction and 
assayed for telomerase activity. This provided a series of dilutions ranging from 1:2 
to 1:10000 as shown in figures 16 and 17 (1:2 corresponded to 200000 cells). 
200000 cells corresponded to a protein concentration of 0.8μg/µl. The results show a 
reduction in absorbance values as the cell lysate was diluted (Figure 16). A 
concentration of 0.02μg/μl of cell lysate equates to 5000 cells. Figure 17 shows the 
corresponding results using protein concentration of the lysates in place of serial cell 
dilution on the x axis. Detectable telomerase activity was demonstrated with a 
C 
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protein concentration of 0.02μg/μl of lysate (produced from 5000 cells), in the PCR 
reaction corresponding to total protein of 40ng in the reaction itself.  
 
 
 
 
 
Figure 16 Relationship between serial dilution of A549 cell lysate / protein concentration and absorbance 
in the telomerase assay. 1:1 ratio represents lysate produced from 200000 cells which was serially diluted  
(1:1 = 200000 cells which has a protein concentration of 0.8 μg/μl). 
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Figure 17 Protein concentration of the serially diluted lysates shown in figure 16.  
Results show absorbance values from single determinations in a single experiment. 
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3.3 Detection of telomerase activity in saliva 
3.3.1 Epithelial cells in saliva 
In order to assess the cell composition of saliva, a series of saliva smears obtained 
from 2 healthy volunteers were prepared and stained with haematoxylin and eosin. 
Figure 18 is a representative smear showing the presence of squamous epithelial 
cells and inflammatory cells.  
 
 
Figure 18 Haematoxylin and Eosin stain of saliva smear showing: A - nucleated squamous epithelial cells 
which appear flat with irregular shapes, B - inflammatory cells and C – debris. 
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Figure 19 Trypan blue exclusion showing nonviable and viable cells from healthy volunteers 
 
The viability of these cells was subsequently determined using trypan blue exclusion 
shown in figure 19 above. Of the 27 cells, only 2 cells (7% of all the cells) showed 
uptake of tryphan blue, indicating 93% viability of the cells. The results suggest 
majority of the cells in the oral rinses were viable.  
3.3.2 Determination of telomerase activity in saliva 
In the following experiments, validation of the telomerase assay was performed in 
human saliva samples ‘spiked’ with telomerase positive A549 cells.  
Effect of saliva and solutions for collection of saliva on telomerase assay 
In order to assess the effect saliva, and the effect the solutions used for the 
collection of saliva may have on the TRAP assay, telomerase activity in A549 cells 
was determined in the absence and presence of saliva samples collected from 
healthy volunteers. This was achieved by adding a known number of A549 cells 
(2x105) to oral rinses obtained from the healthy volunteers (by asking them to gargle 
with either Hartmann’s or saline solutions). The A549 cells were those prepared as 
cells extracts and stored at -800C. The results of a single experiment are shown in 
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figure 20. There were no obvious differences between the absorbance obtained 
using lysates from: (i) A549 cells alone, (ii) A549 cells added to oral rinses obtained 
using either Hartmann’s or saline solution or (iii) A549 cells added directly to 
Hartmann’s or saline solution (without oral rinses). Neither saliva, Hartmann’s nor 
saline solution had any effect on the telomerase assay. The absorbance obtained did 
not appear to be affected by the storage condition of the cell pellet at -800C. 
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Figure 20 Effect of saliva and the solutions (Hartmann’s and saline) used for saliva collection on the 
telomerase assay. C – A549 cells in absence of saliva; H – Hartmann’s solution, S – saline solution; 
H+C/S+C – addition of cells to Hartmann’s / saline solution in absence of saliva; saliva +H+C/saliva +S+C 
– addition of cells to saliva collected by gargling with Hartmann’s solution/saline solution. The results are 
representative results showing the absorbance values from duplicate determinations in a single 
experiment. 
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Effect of the method of saliva collection on telomerase assay 
In order to determine if the collection protocol affected the telomerase activity 
detected, oral rinses were collected from healthy volunteers by gargling with 3mls or 
10mls of Hartmann’s or saline solution. The results show similar absorbance values 
with each method of collection (Figure 21). Therefore, future studies were designed 
such that 10mls of saline was used as the solution to gargle. 
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Figure 21 Effect of method of collection of saliva on absorbance value. C only –A549 cells in saliva; S – 
saline; H – Hartmann’s; S3/S10 – gargle with 3ml /10ml of saline plus A549cells; H3/H10 – gargle with 
3ml / 10ml of Hartmann’s solution plus A549 cells. The results are representative results showing the 
absorbance values from duplicate determinations in a single experiment. 
 
 
3.3.3 Telomerase activity in patient saliva samples and controls 
Patients newly diagnosed with HNSCC were recruited with ethical consent as 
previously described (n = 14). Saliva samples obtained were first of all assayed to 
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determine the protein concentration in each sample. Next, each sample was 
assessed for telomerase activity using the TRAP assay (TeloTAGGG Telomerase 
PCR ELISA kit - see materials and methods). Control samples (n= 13) were obtained 
and assayed similarly. For each patient sample, the maximum volume of lysate 
(25µl) that could be used in the PCR reaction was used. The concentration of protein 
in the 25µl volume of lysate varied between patients but was routinely between 
0.002µg/µl and 0.34µg/µl (corresponding to a total amount of protein in the assay of 
50ng and 8.5µg respectively), see figure 22 below.  
 
 
 
Figure 22 Protein concentration (μg/μl) of lysate for each patient (25μl of lysate was used in the PCR 
reaction). 
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Figure 23 Protein concentration (μg/μl) of lysate for each Healthy control  
 
As shown in figure 17, protein concentration as low as 0.02µg/µl (corresponding to 
total protein of 40ng), produced detectable telomerase activity and the protein 
concentration values obtained in some patients was above the amount of protein 
required to detect telomerase activity. However, the results obtained from patient 
samples show low absorbance values obtained in all samples. The results shown in 
figure 24 are typical of 3 other similar experiments using the same patient samples. 
There were no obvious differences between the two groups (patients and healthy 
controls). 
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Figure 24 Telomerase activity in clinical samples. A – Samples from patients diagnosed with oral cancer 
(P - patient). B – Samples from healthy individuals of matched age and sex (HC – healthy controls). 
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3.3.4 Detection of telomerase hTERT protein expression in cells and tissue  
First of all, hTERT expression was detected using immunocytochemistry in H157 
cells – an oral squamous cell carcinoma cell line shown to be telomerase positive 
and in HUVEC cells shown to be telomerase negative. Telomerase expression was 
then determined in the patient tissue samples using immunohistochemistry. 
Immunocytochemical detection of hTERT antibody  
hTERT protein expression was determined in H157 (telomerase positive) and 
HUVEC cells (telomerase negative), see figure 53. H157 and HUVEC cells were 
cultured in 8 well chamber microscopic slides until they achieved 70% confluence. In 
order to determine the best concentration of antibody to use, different concentrations 
of hTERT antibody were produced by dilution with 1% goat serum (1:200, 1:100 and 
1:50). Each concentration was applied to a pair of wells on the slides, and in the 4th 
pair of wells, the antibody was omitted in order to provide a negative control. Positive 
hTERT staining (heterogenous brown staining) was observed using the different 
dilutions of primary antibody in the H157 cells but not in the negative controls in 
which the antibody was omitted, indicating that there was hTERT protein expression 
in H157 cells (figures 25 and 26). The brown staining was most intense with 1:50 
dilution of the antibody. There was no hTERT staining seen in the HUVEC cells or 
controls (Figure 27). From these series of experiments, 1:50 dilution of the antibody 
was selected as the primary antibody dilution used. 
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Figure 25 hTERT expression in H157 cells. A 1:100 dilution of antibody. B 1:50 dilution of primary 
antibody. Taken at 20x objective lens magnification 
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Figure 26 Absence of hTERT expression in H157 cells in the negative controls in which the antibody was 
omitted. Taken at 20x objective lens magnification 
 
102 
 
Figure 27 Absence of hTERT expression in A - HUVEC cells with 1:50 dilution of primary antibody and 
B – HUVEC cells negative controls. Taken at 20x objective lens magnification 
B 
A 
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Immunohistochemical detection of hTERT antibody  
A549 xenografts were derived from subcutaneously grown tumours in NCR/Nu mice, 
as described in materials and methods (sections 2 and 3). Patient tissue samples 
were obtained with ethical consent from some patients in the same group as in the 
saliva study (not all the patients had tissue samples available). Expression of hTERT 
was initially determined and validated in xenograft tissue derived from the A549 
cells. 
Determination of best antigen retrieval method  
In order to optimize the experimental technique, two different antigen retrieval 
methods were compared: one using the microwave and another with the oven. Both 
methods were performed using different concentrations of primary antibody as well 
as no antibody - negative control, (see materials and methods). Using the microwave 
technique, the slides were immersed in antigen retrieval solution and heated in the 
microwave for 20 min or 10 min and one set of slides were not heated the 
microwave. Using the oven technique, the slides were immersed in the antigen 
retrieval solution, and then placed in the oven at 90oC for 40 min. The results are 
shown in figures 28 to 34 below. Results show heterogenous brown staining in the 
nuclei and cytoplasm in the xenografts, with increasing intensity of staining using the 
increasing primary antibody concentrations. There was no staining in the negative 
controls which had no antibody. There was no difference in the intensity of staining 
using the different methods of antigen retrieval. The microwave technique involving 
heating the slides for 20 minutes was therefore used for further experiments. Based 
on the good intensity of staining using 1:50 dilution of the primary antibody, this was 
selected as the antibody dilution used for further studies.  
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Figure 28 hTERT expression in A549 xenograft using the microwave antigen retrieval technique (10 min 
microwave): A 1:50 primary antibody dilution, B 1:100 primary antibody dilution. Taken at 20x objective 
lens magnification.  
A 
B 
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Figure 29 hTERT expression in A549 xenograft using the microwave antigen retrieval technique – (10 
min microwave): A 1:200 primary antibody dilution, B negative control. Taken at 20x objective lens 
magnification 
A 
B 
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Figure 30 hTERT expression in A549 xenograft using the microwave antigen retrieval technique (20 min 
microwave): A 1:50 primary antibody dilution, B 1:100 primary antibody dilution. Taken at 20x objective 
lens magnification 
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Figure 31 hTERT expression in A549 xenograft using the microwave antigen retrieval technique - 20min 
microwave: A 1:200 primary antibody dilution, B negative control. Taken at 20x objective lens 
magnification 
 
A 
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Figure 32 hTERT expression in A549 xenograft using the microwave antigen retrieval technique (no 
microwave): A 1:50 primary antibody dilution, B 1:100 primary antibody dilution. Taken at 20x objective 
lens magnification. 
A 
B 
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Figure 33 hTERT expression in A549 xenograft using the microwave antigen retrieval technique (no 
microwave): A 1:200 primary antibody dilution, B negative control. Taken at 20x objective lens 
magnification. 
A 
B 
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Figure 34 hTERT expression in A549 xenograft using the oven method – A 1:50 dilution of primary 
antibody, B negative control. Taken at 20x objective lens magnification 
 
A 
B 
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3.3.5 Expression of hTERT in patient tissue and controls 
Next, hTERT expression was determined in patient tissue samples and from normal 
tonsillar tissue which served as controls. As previously mentioned, tissue samples 
were not available for all patients; therefore results below are a representative 
sample of the results obtained in 3 patients. A 1:50 dilution of primary antibody was 
used and antigen retrieval was performed by immersing the slides in antigen retrieval 
solution and heating the slides for 20 minutes in the microwave (as described in 
section 3.2.8). Patient tissues expressed heterogenous brown staining indicating 
hTERT expression, whilst the negative controls (without the primary antibody 
added), and normal tonsillar tissue did not show brown staining (figures 35 – 38). 
 
 
Figure 35 Absence of hTERT expression in normal human tonsillar tissue using 1:50 dilution of primary 
antibody. Taken at 20x objective lens magnification. 
 
112 
 
 
Figure 36 hTERT expression in patient tissue sample – patient 1. A - using 1:50 dilution of primary 
antibody, B - negative control. Taken at 20x objective lens magnification. 
A 
B 
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Figure 37 hTERT expression in patient tissue sample – patient 2. A - using 1:50 dilution of primary 
antibody, B - negative control. Taken at 20x objective lens magnification. 
A 
B 
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Figure 38 hTERT expression in patient tissue sample – patient 3. A - using 1:50 dilution of primary 
antibody, B - negative control. Taken at 20x objective lens magnification. 
A 
B 
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3.4 Telomerase inhibition  
In parallel with studies to investigate telomerase in tissue and saliva samples from 
HNSCC patients, studies were also undertaken to characterize compounds with 
putative telomerase inhibitory activity. The compounds were synthesized at the 
School of Pharmacy, University of Bradford.  
In these series of experiments, a methodology for determining the activity of novel 
compounds on telomerase activity was derived by first assessing the stability of the 
enzyme at experimental temperatures (370C) over time and also determining the 
effect of the compounds solvent (DMSO) on the TRAP reaction. In order to assess 
the direct effects of the compounds on telomerase activity, A549 cells lysates were 
incubated with the compounds for varying lengths of time and then the remaining 
telomerase activity was measured. 
 
3.4.1 Stability of telomerase at 370C with time 
To determine the stability of telomerase in the cell lysates, A549 cell lysates were 
incubated at 370C for different time periods (20 min to 240 min). The results in figure 
39 showed that the enzyme was stable for up to 120 min (2h). After 120 min, the 
telomerase activity (represented by the absorbance values) began to decline. 
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Figure 39 Stability of telomerase enzyme at 370C with time. 
A, incubation of A549 cell lysate at 370C from 0 min (no incubation) to 60 min. B, incubation at 370C from 
0 min to 240 min. The results are representative results showing the absorbance values from duplicate 
determinations in single experiments. 
 
 
A 
B 
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3.4.2 The effect of DMSO on the TRAP reaction 
DMSO was used as solvent for a few of the compounds screened. The effect of 
DMSO on the TRAP reaction within the telomerase PCR ELISA kit was therefore 
assessed by adding 100% DMSO to aliquots of A459 cell lysate (produced from 
2x105 cells) to make final DMSO concentrations of 5, 2.5, 1, 0.5, 0.25 and 0.1% (v/v). 
The lysates were then immediately assayed for their telomerase activity. The results 
are shown in figure 40. There appeared to be no change in the absorbance values 
obtained in the presence of different concentrations of DMSO, suggesting that 
DMSO did not affect telomerase activity. The concentration of DMSO subsequently 
used in the experiments was typically 0.1% however. 
  
 
Figure 40 Effect of DMSO on the telomerase activity in A549 cell lysates. (A549 control - A549 cell lysate 
without DMSO). The results are representative results showing the absorbance values from duplicate 
determinations in a single experiment. 
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3.4.3 Effect of known cytotoxic agents on telomerase activity 
In order to determine the effect of some established cytotoxic agents on telomerase 
activity, 5 fluorouracil, cisplatin and doxorubicin were selected for testing. An initial 
stock concentration of 1mM of each agent was prepared. This was added to A549 
cell lysates (prepared from 2 x 105 cells) to make final concentrations of 200µM 
which were then incubated at 370C for 2h. The results are shown in figure 41. The 
results show complete inhibition of telomerase activity by doxorubicin and partial 
inhibition by 5 fluorouracil, but no inhibition by cisplatin.  
 
 
 
 
Figure 41 Effect of 5FU, doxorubicin and cisplatin on telomerase activity in A549 cell lysates. The results 
show the mean absorbance values from duplicate determinations in a single experiment 
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3.4.4 Berberine chloride as a positive control 
Berberine chloride was selected as a positive control to develop an experimental 
technique for screening novel compounds (it was shown to be a moderate inhibitor of 
telomerase by Naasani et al in 1999). In order to assess the ability of berberine 
chloride to inhibit telomerase activity under the assay conditions used to screen the 
compounds, berberine chloride in aqueous solution was added to aliquots of A549 
cell lysate (produced from 2x105 cells). Final concentrations of 200, 20, 2 and 0.2µM 
were produced. The control was A549 cell lysate (termed A549 control) plus a 
volume of water equal to the drug volume was used. The effect of adding berberine 
chloride to cell lysates without incubation, and then addition of 200µM of berberine 
chloride over a time period of 30, 60 and 120min was first determined. Berberine 
chloride did not produce an immediate inhibition of telomerase activity when it was 
not incubated with the lysates as shown in figure 42. However, after incubation of the 
cell lysates over time with 200µM of berberine chloride, absorbance values were 
reduced (figure 43). This reduction in telomerase activity was most marked at 
120min (2h). Based on this, the effect of different concentrations of berberine 
chloride on the cell lysates after 2h incubation was then determined (figure 44). The 
maximum inhibitory activity of berberine chloride occurred at 200μM.  
From this series of experiments, 2h was selected as the exposure time of the cell 
lysates to the compounds as it was shown that the enzyme remained stable for up to 
2h at 370C in figure 39, and also the reduction in telomerase activity after exposure 
to 200μM of berberine chloride over a time period was most marked at 2h. 
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Figure 42 Effect of berberine chloride on telomerase activity in A549 cell lysates without incubation. The 
results are representative results showing the absorbance values from duplicate determinations in a single 
experiment. 
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Figure 43 Effect of 200μM of berberine chloride on A549 cell lysates over a time period compared to 
lysates not exposed to berberine chloride. The results show mean absorbance values from 4 
determinations in a single experiment 
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Figure 44 Effect of a range of concentrations of berberine chloride on telomerase activity in A549 cell 
lysates following 2h incubation. The results show the mean absorbance values from duplicate 
determinations in a single experiment 
 
3.4.5 Inhibition of telomerase activity in A549 cell lysates 
In the following series of experiments, the effect of a series of novel compounds on 
the telomerase activity in A549 cell lysates was assessed. 34 compounds were 
screened for telomerase inhibition, of which 19 compounds appeared to inhibit 
telomerase activity. The inhibitory effects of these compounds were further assessed 
by determining if the inhibition was a result of non-specific inhibition of the PCR 
reaction in the assay protocol. A549 cell lysates were incubated with the compounds 
for 2h as described in section 3.3.1. In order to determine which of the 34 
compounds could be possible inhibitors of telomerase activity, the compounds were 
added to the cell lysates to make a final concentration of 200µM. All 9 water soluble 
compounds appeared to inhibit telomerase activity (figure 45), whilst only 10 of the 
25 DMSO soluble compounds were identified as having inhibitory activity (figure 46). 
Both experiments were performed twice and figures 45 and 46 show representative 
results. 
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Figure 45 Inhibition of telomerase activity in A549 cell lysates by water soluble compounds (200μM 
concentration) after 2h exposure. A549 control – A549 cell lysate with water. The results show the mean 
absorbance values from duplicate determinations in a single experiment.  
 
 
 
 
Figure 46 Inhibition of telomerase activity in A549 cell lysates by DMSO soluble compounds (200μM 
concentration) after 2h exposure. A549 control was A549 cell lysate with 0.1% DMSO. The results show 
the mean absorbance values from duplicate determinations in a single experiment.  
 
 
123 
 
3.4.6  Effect of compounds on telomerase PCR reaction 
The first step of the TELOTAGG Telomerase PCR ELISA test is a modification of the 
original TRAP assay. It has two parts: the first part involves addition of telomeric 
repeats to biotin labeled synthetic primers by telomerase followed by amplification of 
these elongation products by PCR. In the second part, the PCR product is denatured 
and hybridized to a detection probe, this is then immobilized, and the resulting 
product visualized by ELISA. It was therefore important to eliminate the possibility 
that the telomerase inhibitory activity of the compounds in the cell free assay was not 
due to an effect of the compounds on the TRAP assay itself and in particular, the 
PCR step. 
PCR amplification of β actin 
To determine if the inhibitory effect of the compounds was as a result of nonspecific 
inhibition of the PCR reaction, RNA was extracted from A549 cells and reverse 
transcribed into cDNA. The cDNA was then incubated with the compounds and then 
subjected to PCR using β actin primers to amplify this house keeping gene. The 
PCR products were run on an agarose gel. The presence of the β actin PCR product 
confirmed that: 
a) The reverse transcription step was successful  
b) The selected compound did not inhibit the PCR reaction  
The results for the water soluble compounds are shown in figure 47. The presence of 
β actin PCR product in lane 2 served as the positive control to which no drug was 
applied. Lanes 3 and 4 were the negative control lanes using water only. Lanes 6, 7, 
9 and 10 were for LSCMe, LSCEt, HE19 and HE20 respectively. The presence of β 
actin PCR products indicates that these compounds did not inhibit the PCR reaction. 
These results are representative of three similar experiments. The 8 DMSO soluble 
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compounds that appeared to inhibit telomerase activity also inhibited the PCR 
reaction which was indicated by the absence of β actin PCR product on the gel 
(figures 48).  
 
 
 
 
Figure 47 A and B Gel electrophoresis of PCR products showing effect of water soluble compounds on  
β actin PCR amplification. Lanes: 1 (M – master mix) – DNA ladder, 2 - positive control (β actin PCR 
product which was not exposed to compounds), 3 - RT negative control, 4 - negative control using water, 
5 - SJ45, 6 - LSCEt, 7 - LSCMe, 8 - VP1MIT, 9 - HE19, 10 – HE20, 11 HE24, 12 – HE25, 13 HE27.  
Lanes 5, 8, 11, 12 and 13 are water soluble compounds which inhibited β actin PCR amplification. 
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Figure 48 A and B Gel electrophoresis of PCR products showing effect of DMSO soluble compounds on  
β actin PCR amplification. Lanes: 1 (M – master mix) – DNA ladder, 2 - positive control (β actin PCR 
product which was not exposed to compounds), 3 - positive control, 4 - RT negative control, 5 – VP1RR2, 
6 – VP1PIP2, 7 – VP1PRR3, 8 – VP2MITOH, 9 – VP2ME3, 10 – VP2MPH, 11 - mVP2ME3,  
12 – VP2PRR3. Lanes 5 - 12 are DMSO soluble compounds which inhibited β actin PCR amplification. 
   M     2      3      4      5     6      7      8      9     10    11     12   
300 bp 
   M    2     3      4      5      6      7      8      9      10      11     12   
300 bp 
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3.4.7 Effect of selected compounds on telomerase activity  
As presented above, HE 19, LSCMe andLSCEt had no inhibitory effect on the PCR 
reaction (section 4.4.6) and were considered as true inhibitors of the telomerase 
activity. HE20 partially inhibited Taq. They were therefore selected for further 
analysis. The 4 compounds were all water soluble and were added to cell lysates to 
make final concentrations of 200, 100, 50, and 25μM. The results are shown in 
figures 49 -52 and are representative of 2 independent experiments. There was a 
25% decrease in telomerase activity with HE19, HE 20 and LSCMe at 200μM, and 
8% decrease with LSCEt. An IC50 value for each compound is shown in table 8. 
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Figure 49 Effect of HE19 on telomerase activity. The results show the absorbance values from duplicate 
determinations in a single experiment 
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Figure 50 Effect of HE20 on telomerase activity. The results show the absorbance values from duplicate 
determinations in a single experiment 
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Figure 51 Effect of LSCMe on telomerase activity. The results show the absorbance values from duplicate 
determinations in a single experiment 
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Figure 52 Effect of LSCEt on telomerase activity. The results show the absorbance values from duplicate 
determinations in a single experiment 
 
 
 
Compound Mean IC50 (μM)  
HE 19 
HE20 
LSCMe 
LSCEt 
140 
165 
102 
89 
 
Table 9 IC50 values (concentration at which 50% of telomerase activity is lost) in A549 cell lysates 
following 2h exposure to the selected compounds (n=2). 
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3.5 Cytotoxicity of selected compounds 
From the experiments described in section 3.3, four compounds (HE19, HE20, 
LSCMe, LSCet), were selected for further study (see figure 12 for structures of the 
compounds). These compounds were able to inhibit telomerase in the cell free assay 
and did not inhibit the PCR reaction, thus suggesting that they were specifically able 
to inhibit telomerase activity. 
In this section, the relationship between telomerase inhibition and cell cytotoxicity 
was investigated. Cell lines which expressed different levels of telomerase activity 
were identified. Two cell lines were selected, were incubated with the selected 
compounds and cytotoxic effects were assessed using the MTT assay. In order to 
compare the effect of the selected compounds on telomerase positive and negative 
cell lines, A549 cells shown to have telomerase activity and HUVEC cells without 
telomerase activity (figure 53), were also incubated with the selected compounds. 
3.5.1 Telomerase activity in cell lines 
In order to identify telomerase positive and negative cells, telomerase activity was 
determined in a range of cell lines. The results are shown in figure 53 (representative 
of 3 independent experiments). A549, H157, H460, EJ138, HT29, A2780 and 
HT1080 (all human cancer cell lines), had telomerase activity indicated by the high 
absorbance values obtained as compared to HUVEC cells and HS27 cells (normal 
human somatic cells), which showed no telomerase activity. 
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Figure 53 Telomerase activity in telomerase positive and negative cell lines. The results show the mean 
absorbance values from duplicate determinations in single experiments 
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3.5.2 The validation of MTT assay 
The MTT assay was first validated by confirming that there was a linear relationship 
between absorbance at 540nm and A549 cell number. The results in figure 54 are 
representative of 6 independent experiments. The results demonstrate a linear 
relationship between cell number and absorbance. 
 
Figure 54 Relationship between A549 cell number and absorbance at 540nm. Results are mean 
absorbance values from 8 determinations in a single experiment. 
 
 
3.5.3 Plating of HUVEC cells 
1000 cells were seeded into 96 well plates and incubated for 96 hours as was done 
for the cancer cell lines with resultant poor cell survival. Therefore, in order to 
determine the optimal number of HUVEC cells that could be used for the 
chemosensitivity measurements, various concentrations of HUVEC cells in 
suspension were seeded into 96 well plates and incubated for 96 hours as described 
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in 3.3.3. The result in figure 55 shows the absorbance values for different 
concentrations of HUVEC cells. There appeared to be lower absorbance for cell 
concentration of 40000 (4 X 104) suggesting too many cells, and 10000 (1 X 104) 
suggesting too few cells; as compared to 30000 (3 X 104) cells and 20000 (2 X 104) 
cells which good absorbance values. 20000 (2 X 104) cell concentration was 
therefore selected as the concentration used for the chemosensitivity 
measurements. 
 
Figure 55 Relationship between HUVEC cell number and absorbance at 540nm. Results are mean 
absorbance values from 8 determinations in a single experiment 
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3.5.4 Cytotoxicity of selected compounds in vitro 
The response of telomerase positive and telomerase negative cell lines (A549 and 
HUVEC cells) to the 4 selected compounds at 2h and 96 h exposure is presented in 
figures 56 and 57. There were differences in response to the compounds depending 
on the duration of exposure. IC50 values obtained for both 2h and 96h exposure are 
presented in tables 10 and 11.  
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Figure 56 Cytotoxicity of HE19, HE20, LSCMe, and LSCEt on A549 cell line (A, B, C, D respectively). 
Survival curves were obtained for each compound after 2h (○) and 96h (●) exposure to a range of 
concentrations. Each value represents the mean ± SEM for three independent experiments. 8 
determinations were made in a single experiment. 
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Figure 57 Cytotoxicity of HE19, HE20, LSCMe, and LSCEt on HUVEC cells (A, B, C, D respectively). 
Survival curves were obtained for each compound after 2h (○) and 96h (●) exposure to a range of 
concentrations. Each value represents the mean ± SEM for three independent experiments. 8 
determinations were made in a single experiment. 
A
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Novel 
compound 
Acute cell toxicity (A549 cells) Cell free 
assay 
IC50 (μM) at 2h IC50 (μM) at 96h IC50 (μM)  
HE 19 
HE20 
LSCMe 
LSCEt 
>200 
120 
170 
100 
30 
6 
11 
10 
140 
165 
102 
89 
 
Table 10 Comparison between concentrations of novel compounds needed for acute cell toxicity in A549 
cell line and inhibition of telomerase in a cell free assay. 
 
 
 
 
 
Compound IC50 (μM) at 2h IC50 (μM) at 96h 
A549 HUVEC A549 HUVEC 
HE 19 
HE20 
LSCMe 
LSCEt 
120 
120 
170 
60 
100 
10 
60.5 
40 
30 
5.8 
11 
8.5 
10 
3 
8.5 
4.5 
 
Table 11 IC50 values in HUVEC cells and A549 cell line following 2h and 96h exposure to the selected 
compounds 
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3.6 Further evaluation of selected compounds 
The difference in telomerase activity and telomere dynamics between cancer and 
normal cells and also the telomere/telomerase complex offers multiple possibilities 
for inhibition. The selected compounds were previously shown to inhibit telomerase 
activity (4.4.5). In the following series of experiments, the effects of the selected 
compounds on telomerase activity were evaluated further. Here, the aim was to 
determine if the impairment of telomerase function and growth inhibition of the 
tumour cells would lead to induction of senescence. The β galactosidase assay was 
used to determine if growth inhibition led to the occurrence of senescent cells. Cell 
lines selected were the PC3 and A549 cell lines which are both known telomerase 
positive cell lines (Figure 14; Sommerfield et al., 1996). Arsenic was selected as the 
control compound to exhibit senescence (Zang et al. 1999; Chou et al. 2001). 
3.6.1 β galactosidase assay 
It has been shown that interference with telomere architecture and maintenance can 
initiate senescence (Karlseder et al 2002, Leonetti et al 2004). Gowan et al in 2004 
showed that a pentacyclic acridine (RHPS4) was found to be a potent telomerase 
inhibitor in the TRAP assay and to cause irreversible cessation of growth after long 
term culture at non-cytotoxic concentrations in cancer cells. In order to determine if 
the selected compounds were able to cause senescence in nontoxic doses, the 
following experiments were performed. First of all, A549 cells and PC3 cells were 
incubated with arsenic and acute cytotoxic effects were assessed using the MTT 
assay as shown in figure 58. Sub-toxic doses (concentration of compound at which 
90% of cells were viable) were then determined (table 12). 
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Figure 58 Cytotoxicity of Arsenic on A549 and PC3 cell lines. Survival curves were obtained after 96h 
exposure to a range of concentrations. Each value represents the mean ± SEM for three independent 
experiments. 8 determinations were made in a single experiment.  
 
Cell line Arsenic (sub-toxic dose μM) 
PC3 0.02 
A549 0.01 
 
Table 12 Sub-toxic values (concentration of compound at which 90% of cells were viable) in PC3 and 
A549 cells following 96h exposure to arsenic 
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PC3 and A549 cells were then incubated with the selected compounds, the cytotoxic 
effects were assessed, and sub toxic doses were determined (figures 56 and 59; 
table 13).  
 
 
 
 
Figure 59 Cytotoxicity of selected compounds on PC3 cell line. Survival curves were obtained after 96h 
exposure to a range of concentrations. Each value represents the mean ± SEM for three independent 
experiments. 8 determinations were made in a single experiment.  
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Compounds (sub-toxic doses μM) PC3 A549 
HE19 0.75 3 
HE 20 0.6 3 
LSCMe 1.5 3 
LSCEt 1.5 1.5 
 
Table 13 Sub toxic values in PC3 and A549 cells following 96h exposure to the selected compounds 
 
 
In order to perform the β galactosidase study, the cells were incubated with arsenic 
and the compounds in 6 well plates at 370C as previously described (3.3.5). Controls 
had no compounds added. PC3 cells and A549 cells were exposed to sub-toxic 
doses of arsenic and sub-toxic doses of the selected compounds for 5, 10 and 15 
days after which the plates were examined for the presence of senescent cells. 
There was absence of senescent cells after 5, 10 and 15 days in both the plates 
exposed to arsenic as well as to the plates exposed to the selected compounds. This 
implied that the mechanism of cell toxicity of the compounds was not via the 
induction of cellular senescence. 
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4 DISCUSSION 
Cancer is a major disease burden worldwide and deaths from cancer in the world are 
projected to continue rising. It is a major cause of mortality and morbidity in the UK 
with more than 1 in 3 people in the UK developing some form of cancer in their 
lifetime. Cancer is therefore a condition with major socioeconomic impact requiring 
great efforts to improve current strategies for detection and treatment.  
HNSCC is a complex disease and despite therapeutic advances in its treatment, the 
overall 5 year survival from the disease has remained unchanged over the last 30 
years due to diagnostic and treatment challenges. Two issues that would positively 
affect the outcome in HNSCC patients are (i) early diagnosis and (ii) targeted 
treatment. 
The thesis submitted here had 2 general aims: firstly, to investigate the feasibility of 
detection of telomerase activity in saliva of patients diagnosed with upper aero-
digestive tract squamous cell carcinoma using a nonradioactive telomerase PCR-
ELISA method. The aim was to develop a simple technique for detection in both 
primary and recurrent disease. Secondly, to screen a range of novel compounds with 
a view to identifying effective and novel telomerase inhibitors. 
4.1 Detection of telomerase activity in saliva 
The first part of this study was to determine the presence of telomerase activity in 
saliva. Salivary diagnostics using salivary biomarkers specifically for early cancer 
detection has attracted research interest especially for cancers occurring in the oral 
cavity and oropharynx. Sankaranarayanan et al (2013) showed that oral cancer 
screening reduced oral cancer mortality by more than 80 percent in tobacco and/or 
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alcohol users. However, Brocklehurst et al (2010) had previously shown that this 
method of screening which included visual inspection followed by tissue biopsy had 
only 64 percent sensitivity for oral cancer and 31 percent specificity for oral dysplasia 
or cancer. The detection of telomerase activity in saliva of head and neck squamous 
cell cancer patients could be used in conjunction with histological analysis to improve 
screening, diagnosis/staging and treatment. It would be useful as a molecular 
marker, helping to reduce the morbidity and mortality currently associated with the 
disease and improve the prognosis in patients. Therefore, much research effort has 
been dedicated to investigating potential salivary biomarkers. Salivary biomarkers 
represent a promising non-invasive approach for oral cancer detection, and an area 
of strong research interest. Of the many oral cancer biomarkers studied, only a few 
are being translated to clinical practice. An example of this is CD44, a cell surface 
transmembrane glycoprotein which has been found to be a key tumor initiation 
marker, over-expressed in the earliest stages of carcinogenesis and has been shown 
to be an effective tumor marker. Together with total protein, it is detectable in body 
fluids and can be measured with simple, inexpensive assays (Hirvikoski et al 1999; 
Dasari et al 2014; Franzmann et al 2012).  
Telomerase activation has been shown to be an early event in the progression of 
HNSCC (Mao et al 1996). Telomerase activity is commonly determined using the 
TRAP assay which allows semiquantitative and quantitative analysis. In the standard 
TRAP assay, originally described by Kim et al (1994), PCR products were detected 
in polyacrylamide gels using a radioactive label which was introduced using a 
radioactively labeled primer. The drawback of this technique was the radioactivity. In 
this study, the TRAP assay was the preferred method of determining telomerase 
activity, using the telomerase PCR ELISA kit. This provided a way to detect 
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telomerase activity using a non-radioactive technique. The telomerase PCR ELISA 
kit has been used by several investigators to detect telomerase in some body fluids 
such as urine (Melissourgos et al. 2003), pleural and ascitic fluid (Yamamoto and 
Hirakawa 2004). Oral rinses of HNSCC patients have also been examined previously 
using radioactive based methods of the TRAP assay (Califano et al 1996; Mutiranga 
et al 1996; Sumida et al 1998). Telomerase activity was detected by these 
investigators, but with a low positive rate. Califano et al in 1996 detected telomerase 
activity in 14 of 44 (32%) oral rinses from patients with HNSCC. They used a 
modification of the method first described by Kim et al (1994), and the PCR products 
were amplified using a radioactive method. This low positive rate was thought to be 
due to a number of factors including the presence of RNase in saliva or storage of 
the saliva samples for prolonged periods at room temperature, both of which could 
degrade the telomerase enzyme activity. A low percentage of cells in the samples, of 
which few were cancer cells, were also thought to be a possible reason for low 
positivity. 
The first aim of this study was to attempt to use a simplified, nonradioactive based 
technique to detect telomerase activity in saliva of HNSCC patients who had a 
histological diagnosis of the condition. This was beneficial as it avoided the use of 
radioactive substances. To my knowledge; no other investigators at the time had 
attempted to do this using the non radioactive technique.  
First of all, the Haemotoxylin and Eosin stain was used to demonstrate the presence 
of epithelial cells in saliva (figure 18). The viability of these epithelial cells was then 
determined by trypan blue exclusion (figures 19). This demonstrated the presence of 
epithelial cells in the saliva smear which were then shown to be viable. 
144 
 
Determination of the exact number of epithelial cells present in the saliva samples 
could not be carried out reliably due to the significant amount of debris in the 
samples. This was despite ensuring saliva was collected at least 2 h or more after 
consumption of food or drink.  
As previously mentioned, it has been shown that saliva contains endogenous RNA 
(Li et al 2004) as well as ribonucleases (Eichel et al 1964; Bardon and Sugar 2004), 
but it is unclear how these coexist. These RNases could potentially degrade the RNA 
subunit of the telomerase enzyme. In this study, it was shown that the telomerase 
enzyme activity was preserved despite the presumed presence of endogenous RNA 
in saliva. A549 cell pellets (produced from 2 x 105 cells, stored at -800C) were added 
to the saliva samples obtained by asking volunteers to gargle, in order to determine if 
the telomerase enzyme would be active in the presence of saliva and under the 
storage conditions of -800C. The saliva samples were immediately tested for 
telomerase activity after addition of the cells and results showed that added 
telomerase could be detected in the saliva samples indicating that telomerase 
activity was preserved in saliva. The telomerase activity also did not appear to be 
affected by the storage condition of the cell pellet at -800C. In addition, as seen in 
figure 20, neither saliva nor the solutions used for collection affected the telomerase 
activity.  
As saliva is a viscous fluid, it was noted that centrifugation of the saliva samples 
without further addition of either Hartmann’s or saline solution, produced a poor 
pellet. Several methods of collecting saliva samples were therefore tried in healthy 
controls to improve the yield of cells and formation of pellets after centrifugation. 
Comparing the methods of using 3 ml of solution to gargle followed by addition to the 
sample of a further 15 ml of solution and using 10ml of solution to gargle (without 
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further addition of solution), there was no apparent difference in the telomerase 
activity obtained (figure 21). In both cases, 2x105 A549 cells were added to the 
samples prior to centrifugation. Centrifugation at 1000g and 1500g was compared, 
and it appeared that a better pellet was obtained using 1500g.  
The degree of sensitivity of the telomerase PCR ELISA kit was determined by 
looking at the effect of serially diluting cells before lysates were prepared and serially 
diluting the cell lysates themselves. When the cells were serially diluted, there was a 
linear relationship between cell concentration and absorbance values obtained in the 
assay when cell number was above 1000 cells per ml of suspension. Below 1000 
cells/ml, there was a sharp drop in the absorbance value, and even though the kit 
detected telomerase activity at cell counts as low as10 cells/ml, there was 
inconsistency in the absorbance values detected below 1000 cells/ml (figure 15). 
The cell lysates were also serially diluted in order to determine degree of sensitivity 
of the kit, by determining the lowest protein concentration that would produce a high 
absorbance (indicating positive telomerase activity). The value obtained appeared to 
be in the range of 0.02μg/μl to 0.8μg/μl (corresponding to a total amount of protein in 
the assay of 40ng to 1.6μg) as shown in figure 16. This was produced from 5000 – 
200000 cells. 
In this study, saliva samples in form of oral rinses were collected from a total of 28 
subjects. 14 patients with oral cancer and 14 control subjects. Patients with oral 
cancer were selected from the head and neck cancer patients in order to provide a 
best possible chance of collecting representative tumour cells. Samples of saliva 
collected from the patients failed to show distinct telomerase activity (figure 24). As 
shown previously, telomerase activity could be detected using volumes of lysates 
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which contained a minimum of 40ng of protein (figure 16). In the cell lysates obtained 
from the patient samples, the amount of protein which was used in the PCR reaction 
was in the range of 50 ng to 20µg (figure 22). These results indicate that there 
should have been enough cells to produce lysates in the saliva sample which would 
produce detectable telomerase activity, if the cells were expressing the enzyme. 
Figure 19 showed that viable cells were demonstrated in the saliva samples and the 
telomerase PCR ELISA kit can detect cell counts as few as 10 cells/ml (figure 15). 
The absence of telomerase activity in patient samples could therefore have been as 
a result of low numbers of cancer cells in the saliva samples which may have been 
below the threshold needed for detection or there were no telomerase positive cells 
shed into the patient samples. Califano et al (1996) noted that the destruction of the 
telomerase enzyme by RNases could have been a factor responsible for poor 
detection. In this study we were able to demonstrate that exogenous telomerase 
enzyme activity was maintained in the presence of saliva. Another factor for failure to 
detect telomerase activity in the patient samples could be the collection and storage 
conditions of the samples. The samples were collected and immediately placed on 
dry ice, then centrifuged within 10 min after which they were frozen and stored at -
800C until use. There is a possibility that enzyme activity was lost within this time 
period. However, A549 cells used in a series of experiments (figures 14) were 
obtained from cell pellets stored at -800C which did not affect the telomerase activity.  
Ohyashiki et al (1997) were able to specifically identify telomerase positive cells in 
range of cell lines using in situ PCR. In the future, this method might be a possible 
way of determining if the cells seen on the saliva smears were actually cancer cells 
and help as a further diagnostic aid.  
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4.2 Detection of hTERT protein 
Human telomerase consists of two major components: human telomerase RNA 
(hTR) which acts as a template for reverse transcription, and human telomerase 
reverse transcriptase (hTERT), the catalytic subunit which has reverse transcriptase 
activity. hTERT is believed to be a critical step in the production of telomerase 
activity. The expression of hTERT subunit has been shown to correlate well with 
telomerase activity and hTERT gene expression is generally repressed in normal 
human cells and up regulated in tumour cells (Meyerson et al 1997, Nakayama et al 
1998, Ritz et al 2005). Hiyama et al in 2001 were able to detect the presence of 
hTERT protein at the cellular level in paraffin embedded tissues which had 
previously been reported to have telomerase activity. They were able to detect 
hTERT protein using immunohistochemistry in cultured cells and tissue sections 
obtained from a variety of tumour tissues such as breast, lung, stomach and colon. 
They showed that there was little background nonspecific staining of cell types that 
were believed to be telomerase negative. H157 is a human oral squamous cell 
carcinoma cell line and telomerase activity was shown to be present in this cell line 
using TRAP assay (figure 53). HUVEC cells (which are normal human cells), were 
shown not to possess telomerase activity (figure 53). 
As there was failure to detect telomerase activity in the saliva of the selected 
patients, a further study was done to determine the presence of telomerase in the 
selected oral cancer patients from whom saliva samples were obtained. Here, we 
aimed to determine the presence of telomerase hTERT protein in formalin fixed, 
paraffin embedded tissue samples of the patients using immunohistochemistry. 
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First of all, the presence of hTERT protein expression was determined in H157 cells 
using immunocytochemistry. Three different dilutions of the primary antibody (1:200, 
1:100 and 1:50) were used to determine the dilution that would produce the best 
intensity of immunostaining. The presence of brown staining was indicative of 
hTERT expression. The most intense brown staining was obtained using the 1:50 
primary antibody dilution (figure 25). 1:50 dilution of the primary antibody was 
therefore selected as the primary antibody concentration used. There was no 
staining observed in the HUVEC cells or negative controls (which had no antibody) 
(figures 26 and 27). This finding is indicative of the correlation between the presence 
of telomerase activity and the expression of hTERT. 
Next, the presence of hTERT protein in patient tissue samples was assessed using 
immunohistochemistry. The methodology was developed by using A549 xenografts 
derived from subcutaneously grown tumours in NCR/Nu mice. First of all, two 
different antigen retrieval methods were compared: one using the microwave and 
another with the oven. Three different dilutions of the primary antibody were used 
(1:200, 1:100 and 1:50), the negative control was without antibody. In the 
experiments performed using the microwave technique, different time periods of 
microwave heating were performed - (20 min, 10 min and no microwave heating). In 
order to determine the best method of antigen retrieval, both the microwave method 
and the oven method of antigen retrieval were performed. The microwave technique 
of antigen retrieval involving heating the slides for 20 minutes was selected for 
further experiments as there was no difference in the intensity of staining using the 
different methods of antigen retrieval (figures 28 – 34). 1:50 dilution of the primary 
antibody (figure 30A) was selected as the antibody dilution used for further studies 
as this produced the best intensity of brown staining. Paraffin embedded tissue 
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samples were obtained for 7 out of the 14 patients and in all cases, there was brown 
staining indicative of hTERT protein expression.  
In this study, using the TRAP assay, saliva samples from all 14 patients did not show 
telomerase activity; however, it was possible to detect hTERT protein expression in 7 
of the 14 patient tissue samples. Despite the failure to detect telomerase activity in 
the saliva samples of selected patients, the detection of hTERT protein expression in 
some patients indicates that there was likely to be telomerase activity present in the 
patient’s tumour cells, but we were unable to detect it in saliva for reasons stated 
above. Work on salivary biomarkers for oral cancer detection has been extensively 
reviewed by Cheng et al in 2014 and emerging issues / challenges preventing the 
use of reliable salivary biomarkers in the clinical setting were identified. These issues 
include a lack of standardization for saliva sample collection, processing, and 
storage; and wide variability in the levels of potential oral cancer salivary biomarkers 
in both non-cancerous individuals and oral cancer patients. These issues and 
challenges are likely applicable in this study. 
 
4.3 Telomerase inhibition 
The management of malignant disease remains one of the most challenging areas of 
modern medicine, and despite advances in the use and development of conventional 
cytotoxic agents, the cure rate remains disappointing in most patients with advanced 
disease of common solid tumours (Keith et al, 2002). This poses a problem 
especially in head and neck cancer patients in whom a significant proportion present 
with locally advanced and unresectable disease. Research into the mechanisms of 
cancer pathogenesis as discussed previously has resulted in the introduction of 
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mechanism based, targeted therapies to treat cancers which can be categorized 
according to their effects on one or more of the hallmark capabilities (figure 4; 
Hanahan and Weinberg 2011). Targeting the hall mark ‘enabling replicative mortality’ 
by looking at possible telomerase inhibitors has been a focus of this thesis. 
Telomerase activity is usually repressed in human somatic tissues and highly active 
in most tumours (section 1.7). Telomerase activity has been validated as an 
anticancer drug target in studies that reported that the over expression of dominant – 
negative hTERT mutants resulted in telomerase inhibition with subsequent telomere 
shortening and eventually senescence or crises (Hahn et al, 1999; Zhang et al, 
1999). Telomerase can therefore be considered an attractive target for cancer 
therapy as cancer cells would be targeted whereas, the remaining healthy tissue 
would be largely unaffected. In addition to this, there is also a possibility that 
telomerase inhibitors may be employed in combination with established cytotoxic 
therapy to aid their effectiveness (Baudino et al. 2015). Different approaches to the 
inhibition of telomerase activity have been under development for more than two 
decades. Various approaches to the inhibition of telomerase expression has been 
reviewed by Jarstfer et al (2013). Mechanisms by which this is done include directly 
targeting the telomerase (hTERT or hTR) or targeting the telomere, targeted gene 
therapy and telomerase-based immunotherapy of cancer (figure 10; table 2). 
Examples of previously investigated compounds include small molecules such as 
AZT (3’-azido-2’, 3’-dideoxythymidine) which are nucleoside analogues with reverse 
transcriptase inhibitory effect and therefore would potentially inhibit hTERT (Strahl 
and Blackburn 1996; Melana et al 1998). These compounds lacked selectivity for 
telomerase, and this therefore limited this approach.  
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BIBR1532 is a nonnucleoside inhibitor of telomerase which has been extensively 
studied in vitro and in vivo (Damm et al 2001; Pascolo et al 2002). BIBR1532 
demonstrated potent inhibition of telomerase in cell free assays. The draw back with 
this group of compounds was that cellular effects required an extensive period of 
exposure to the compounds (~100 days), to allow the telomeres to shorten to critical 
lengths.  
Another strategy at targeting telomerase has been through various antisense-based 
molecules of which the most advanced is GRN163L. GRN163L, also called 
Imetelstat, has been one of the most widely developed direct inhibitors of 
telomerase. It acts as a direct telomerase inhibitor by antagonistically binding to the 
RNA template of telomerase (hTR). GRN163L has been shown to inhibit telomerase 
activity with resulting senescence and apoptosis after progressive telomere 
shortening in various cell lines (Asai et al. 2003; Gellert et al. 2006; Chiappori et al. 
2015). Imetelstat has been undergoing clinical trials for several years. Recent clinical 
development of Imetelstat include studies on patients with myelofibrosis (IMbark™ 
study), and on patients with myelodysplastic syndrome, called (IMerge™ study). 
These studies are currently recruiting targeted patients at various centers in the 
USA, Europe and Asia.  
The telomerase inhibitors such as GRN163L which target telomerase components 
act by causing progressive telomere shortening and induction of cellular senescence 
after a lag phase. The possible drawback of this is that it would take a significant 
amount of time for the action of the drug to become apparent, but if used in 
conjunction with other agents, the effect might be beneficial. For this reason, 
telomerase inhibitors are now being tested in combination with conventional cancer 
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therapy and in maintenance clinical trials aimed at reducing recurrence after surgery, 
chemotherapy or radiation therapy (Baudino et al. 2015). 
Several compounds have been developed to target the telomere and some of these 
exploit the ability of G – rich sequences of DNA like telomeres to fold into 4 stranded 
(quadruplex) intramolecular structures. The novel compounds used in this study can 
be described as G – quadruplex stabilizers. The stabilization of G-quadruplexes can 
prevent telomerase from accessing and elongating the telomere. As mentioned 
previously, telomeric DNA is capable of folding into four-stranded guanine (G4) 
quadruplex structures and in order for telomeric DNA extension to occur, telomerase 
must hybridize to its DNA primer which it is unable to do in the presence of G - 
quadruplex formation. This offers a potential means to selectively target telomeric 
DNA rather than other regions of the genome (Zahler et al 1991).  
Increasing evidence has shown that most G- quadruplex ligands confer their 
biological activity through interaction with telomeric G-rich single strand overhang 
thereby affecting telomere capping state and leading to relatively rapid senescence 
and or apoptosis (Karlseder et al 2002; Salvati et al. 2007). This is compared to 
direct telomerase inhibitors (such as GRN163L and BIBR1532), which require a lag 
period (during which time there is loss of the telomere), before the effect of drug 
becomes apparent. The therapeutic potential of G quadruplexes ligands has resulted 
in a rapidly increasing number of studies in which small molecule ligands have been 
used to act as G quadruplex stabilizers (Shalaby et al. 2013). However, cellular and 
in vivo data are only available for a small number of these compounds (Neidle. 
2010). A range of G – quadruplex interactive compounds has been developed over 
the years which have demonstrated telomerase inhibition. Disubstituted 
anthraquinones (Sun et al 1997) were the first small molecule G – quadruplex 
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telomerase inhibitors described. One of the most studied small molecule G- 
quadruplex stabilizer is Telomestatin. Telomestatin is a natural product which has 
the ability to inhibit telomerase activity at nanomolar concentrations. It was first 
isolated from the bacteria Streptomyces Anulatus by Shin-ya and co-workers in 2001 
(Shin-ya et al. 2001). The IC50 value of telomestatin was calculated based on 
modified TRAP assay methods. Since telomestatin interferes slightly with PCR 
reaction, the IC50 values ranged from 58 to 600 nM with various primers in variants 
of TRAP assay method (Reed et al. 2008). Telomestatin was found to impair glioma 
stem cell survival and growth through the disruption of telomeric G quadruplex 
(Miyazaki et al. 2012). So far, no study of these compounds has as yet progressed to 
clinical evaluation.  
Other G - quadruplex inhibitors described include cationic porphyrins such as 
TMPyP4 (Fujimori et al. 2011; Mikami-Terso et al 2009), trisubstituted acridines such 
as BRACO19 (Burger et al. 2005), and pentacyclic acridines such as RHPS4 
(Gowan et al 2001; Salvati et al. 2007). One of the draw backs of early G quadruplex 
inhibitors was the relative lack of selectivity for 4 (quadruplex) versus 2 (duplex) 
stranded DNA which resulted in similar potencies for inhibiting telomerase in vitro 
and for producing non-specific acute cell toxicity. Quarfloxin is a G quadruplex 
inhibitor that reached clinical trials. It reached phase 2 clinical trials for the treatment 
of neuroendocrine tumours and chronic lymphoid leukaemia (Shalaby et al. 2013). 
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The second aim of this study was to identify an effective inhibitor of the 
telomere/telomerase complex by screening a selected group of compounds. The 
compounds used in this study were designed to target telomeric DNA quadruplexes, 
stabilize them, making them inaccessible to telomerase and therefore indirectly 
result in inhibition of telomerase activity. The anti-telomerase and cytotoxic activity of 
the compounds was investigated. 
4.3.1 Telomerase inhibition by selected compounds in cell free assay 
First of all, the compounds were screened in a cell free assay to determine which 
compounds would inhibit telomerase activity. The effect of the compounds on 
telomerase activity was assessed in vitro using lysates of A549 cell line – a 
telomerase positive cell line (figures 14). This was assessed using the TRAP assay 
within the telomerase PCR ELISA kit. The methodology was developed by using 
berberine chloride – a known moderate telomerase inhibitor as a control. First of all, 
the stability of the enzyme at 370C was assessed over a varying time period (30min 
to 4 h), in order to select the best time period over which to expose the lysate to 
drugs. The enzyme appeared stable from 30min to 2h; but from 3h to 4 h there was 
progressive reduction in the activity of telomerase at 370C. 2h was therefore selected 
as the time period for exposure to drugs (figure 39).  
As DMSO was to be used as solvent in some of the selected compounds, the effect 
of DMSO on the TRAP assay was assessed by exposure of the lysates to different 
concentration of DMSO (5% to 0.25%). There appeared to be no effect of DMSO on 
the absorbance values obtained in the assay and therefore telomerase activity 
(figure 40).  
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The effect of established chemotherapeutic agents such as doxorubucin, 5 
fluorouracil and cisplatin were also assessed (figure 41). Doxorubicin appeared to 
inhibit the telomerase activity, consistent with the previous finding of Zhang et al 
(2002). In contrast, Cisplatin showed no inhibition of telomerase activity although it 
has been reported as a telomerase inhibitor by Burger et al (1997). 
Cell lysates derived from 2x105 cells were initially exposed to different concentrations 
of berberine chloride without incubation of the lysate with berberine chloride. The 
results showed lack of inhibition of the enzyme, indicating that the drug was not 
effective without incubation. The lysates were then incubated in 200μΜ of berberine 
chloride over different time periods (figure 43) and this showed 2h to be the time at 
which maximum inhibition occurred. The lysates were again incubated in a range of 
concentrations of berberine chloride for a 2h period at 370C and this resulted in 50% 
loss of telomerase activity when incubated in 200µM concentration of berberine 
chloride (figure 44). 200µM was therefore selected as the concentration of the 
selected compounds for use. As berberine chloride was used to develop the assay 
protocol, it was not investigated further. The cell lysates were exposed to 200µM 
concentration of the novel compounds over 2h at 370C. 34 compounds were 
screened - 9 water soluble compounds and 25 DMSO soluble compounds. Of these, 
all 9 water soluble compounds and 10 of the 25 DMSO soluble compounds (total 19 
compounds) appeared to inhibit telomerase activity at 200µM concentration (figures 
45 and 46).  
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4.3.2 Specificity of selected compounds for telomerase inhibition 
Next the specificity of the compounds for inhibition of telomerase activity over other 
DNA polymerases (such as Taq polymerase) was assessed. It was necessary to 
determine if this inhibition of telomerase activity by the 19 novel compounds was a 
result of inhibition of the Taq polymerase within the TRAP assay. This was 
determined by examining the effect of the compounds on β actin PCR amplification. 
The results showed 15 of the 19 compounds which inhibited telomerase activity also 
appeared to inhibit the PCR reaction, but 4 compounds did not inhibit the PCR 
reaction (figures 47 and 48). This suggested that the 4 compounds (HE19, HE20, 
LSCMe and LSCEt) were able to inhibit telomerase specifically and these 
compounds were therefore selected for further analysis (figure 12).  
Varying concentrations (200, 100, 50, and 25μM) of the 4 selected compounds 
(HE19, HE20, LSCMe and LSCEt) were incubated with the A549 cell lysate in order 
to determine the IC50 values. The mean IC50 values (the concentration at which 50% 
of the telomerase activity is lost) obtained for 4 selected compounds is shown in 
table 9.  3 of the compounds (HE19, HE20 and LSCMe) exhibited mean IC50 values 
above 100µM. LSCEt was found to be the most potent at 89µM.  
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Structure activity relationships (SAR) 
There are a limited number of structure activity relationships emerging from this 
study. Based upon the data provided in table X describing the ability of compounds 
to (i) inhibit telomerase specifically and (ii) inhibit polymerases in general (as 
indicated by inhibition of both telomerase and Taq) and (iii) no inhibition of 
polymerases, the following structure activity relationships are listed below.   
 
SAR 1: Increasing the potency of selective telomerase inhibitors.  
A comparison of the structures and activity of LSCet and LSCMe (figure 60) suggest 
that the addition of ethyl groups to the nitrogens on both ‘arms’ of the molecule 
(LSCet) may improve the potency of telomerase inhibition (figure 1). IC50 values for 
the inhibition of telomerase were 89 and 102 M for LSCet and LSCMe respectively. 
The differences in potency are small but it suggests that modifications to this site 
may be useful to direct future synthesis of new molecules. 
 
LSCet (telomerase specific inhibitor) 
N N
S
N
S
N
 
 
LSCMe (telomerase and taq inhibitor) 
N N
S
N
S
N
 
 
Figure 60 LSCMe and LSCet are both Telomerase specific but with varying potencies 
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SAR2: Selectivity for telomerase over Taq polymerase. 
A comparison between the structures of LSCme (telomerase specific) and SJ45 (not 
specific for telomerase) demonstrates that the inclusion of an extra carbon into the 
side chain eliminates the selective inhibition of telomerase (figure 61). Modifications 
to the length of the side chain may therefore not be productive for future chemical 
synthesis. 
 
 
LSCMe (telomerase specific inhibitor) 
N N
S
N
S
N
 
 
SJ45 (telomerase and taq inhibitor) 
N N
S NSN
      
Figure 61 Extra CH2 in the side arm of SJ45 destroys selectivity for telomerase 
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SAR3: Comparison between HE19 and HE 24 demonstrated that a pyridine ring but 
not a piperidine ring structure confers selectivity for telomerase (figure 62). This is 
also true for HE24 compared to HE25. The piperidine structure can nevertheless 
confer selectivity for telomerase (LSCMe above) but in this case the side arms 
contain an oxygen compared to a sulphur. The composition of the side arms together 
with the central ring structure are therefore important in terms of conferring selectivity 
for telomerase inhibition. 
HE19 (telomerase specific inhibitor) 
N
O
N
O
N
 
HE24 (inhibitor of both telomerase and taq polymerase) 
N N
O
N
O
N
 
 
HE20 (telomerase specific inhibitor) 
N
O NON
 
  
HE25 (telomerase and taq inhibitor) 
N N
OO NN
 
Figure 62 Piridine ring structure favours telomerase specific inhibition.  
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There are a number of additional structure activity relationships that confer lack of 
activity against both telomerase and taq polymerase. The majority of these are 
modifications to the side arms of the molecules and an example is shown below.  
 
HE-19 (telomerase specific inhibitor) 
N
O
N
O
N
 
 
AC-A (no inhibition of telomerase or taq) 
N
H
N N
H
NN
O O
N N
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4.3.3 Senecence assay 
Senescence is an arrested state in which the cell remains viable but displays altered 
patterns of gene and protein expression. As described previously, the chromosomal 
ends are protected by the telomere which forms a cap at the end of the 
chromosomes. As well as the effect on the elongation of the telomere ends, 
telomerase also stabilizes the telomere through the additional stabilization of the 
telomere cap (Blasco 2002, Masutomi et al 2003, Sung et al 2005). It has been 
shown that interference with telomere architecture and maintenance can initiate 
senescence (Karlseder et al 2002, Leonetti et al 2004). Gowan et al (2001) showed 
that a pentacyclic acridine (RHPS4) was found to be a potent telomerase inhibitor in 
the TRAP assay and to cause irreversible cessation of growth after long term culture 
at noncytotoxic concentrations in cancer cells.  
The ability of the selected compounds to induce cellular senescence was determined 
using the senescence assay. Cells lines selected were the PC3 and A549 cell lines. 
The methodology was developed by using arsenic which has been shown to induce 
DNA and chromosome damage. First of all, A549 cells and PC3 cells were incubated 
with arsenic and the selected compounds, and acute cytotoxic effects were 
assessed using the MTT assay as shown in figure 58. Subtoxic doses were then 
determined (tables 12 and 13). The PC3 cells and A549 cells were exposed to the 
sub toxic doses of arsenic and selected compounds for 5, 10 and 15 days, after 
which the plates were examined for the presence of senescent cells. There was 
absence of senescent cells after 5, 10 and 15 days in both the plates exposed to 
arsenic as well as to the selected compounds. This implied that the mechanism of 
cell toxicity of the compounds was not via the induction of cellular senescence. 
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4.3.4 Acute toxicity of selected compounds 
A key goal in the development of telomerase inhibitors is the selection of compounds 
which have high telomerase activity inhibition at low concentrations, with relatively 
low concentrations for acute cytotoxicity. In order to further explore the effects of the 
4 selected compounds as telomerase inhibitors, telomerase activity was first of all 
determined in a range of cell lines to determine telomerase positive and negative cell 
lines (figure 53). The acute toxicity of the selected compounds was assessed using 
the MTT assay in order to determine cell survival after drug exposure. As described 
previously, the A549 cell line was exposed to varying concentrations of the selected 
compounds. The response of the A549 cell line to the compounds after 2h and 96h 
exposures is shown in figure 56. The IC50 value for cell toxicity for each compound is 
shown in table 10. The IC50 values obtained for cell toxicity at 2h exposure in the 
A549 cell line are comparable to the values obtained in the cell free assay. Further 
experiments were performed to determine the effect of the compounds on 
telomerase negative cells (HUVEC) in order to determine if the acute toxicity effect of 
the compounds was influenced by the telomerase activity of the cell line. HUVEC cell 
line was exposed to varying concentrations of the selected compounds and the 
response to the compounds after 2h and 96h exposures is shown in figures 57. The 
IC50 values obtained at 2h exposure of the compounds to telomerase positive cells 
(A549) and telomerase negative cells (HUVEC) show that a higher concentration of 
HE19 and HE20 is required for acute cell toxicity in the telomerase positive cells. 
Similar concentrations of the compounds cause acute cell toxicity in both telomerase 
positive and negative cells lines at 96 hour exposure (table 11).   
Overall, the 4 selected compounds appeared to inhibit telomerase in a cell free 
assay at similar concentrations required to cause acute cell toxicity at 2h exposure in 
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the A549 cells. This suggested that the selected compounds were telomerase 
inhibitors and caused acute cell toxicity. However, the mechanism of cell toxicity did 
not appear to be via the initiation of senescence.  
.  
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Future work 
The combination of telomerase inhibitors and traditional therapies may be the most 
effective way to target telomerase-positive tumors in the future (Ruden et al 2013). 
Currently, molecularly targeted therapies have become increasingly important in the 
treatment of advanced aggressive cancers (such as non small cell lung cancer and 
melanoma), as the traditional options of management have harmful side effects and 
are ineffective in the control of tumour progression (Rajanna et al 2015).  Due to the 
role that telomeres play in the life cycle of cancers, telomerase and telomere-based 
therapeutics may be able to replace conventional treatments in the future (Ivancich 
et al, 2017). The undesirable side effects that conventional therapies elicit may be 
reduced or eliminated due to the specificity of these treatments. However, the non 
specificity of the compounds selected in this study, could be advantageous as 
multitargeting is a possible way tackling tumour heterogeneity. 
Saliva testing offers advantages due to its non-invasive nature, the ease of collection, 
and storage of specimens, as well as the possibility of collecting multiple samples. 
However, saliva is a viscous fluid and difficulty in measuring precise volumes of viscous 
saliva samples can decrease the accuracy of analytical measurements. Most potential 
biomarkers are present in saliva at low concentrations such that any error in volume may 
give rise to large errors in the concentrations measured. Due to the low concentrations, 
assays with high sensitivity and low limit of detection are required, in addition to high 
selectivity and specificity (Ngamchuea et al. 2017).  One of the challenges faced in 
research into salivary biomarkers is the lack of standardisation for saliva sample 
collection, processing and storage and effect of oral inflammatory conditions on samples 
collected (Rhadika et al. 2016). This had a possible effect in this study.  In the future, a 
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reliable and standardised method of saliva collection would be the first step in validating 
saliva as a biomarker of disease. 
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Appendix VI  
Compounds used in study and their effect on telomerase and Taq polymerase 
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